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General Introduction 
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The prevalence of overweight and obesity has increased worldwide to epidemic pro-
portions (1). Overweight and obesity result from a positive energy balance, with en-
ergy intake exceeding energy expenditure, resulting in storage of excessive energy as 
fat. The increased prevalence of obesity coincided with technological developments, 
like cars, washing machines and television, contributing to sedentary lifestyles, sug-
gesting a causal link (2-6). However, experimental designs are too weak to provide 
evidence for such causal link (7-9). It is unlikely that changes to a more sedentary 
lifestyle are responsible for the obesity epidemic through lowered energy expenditure, 
since physical activity energy expenditure has not declined over the same period that 
the prevalence of obesity increased dramatically (10). The latter implies that an in-
creased energy intake is responsible for the energy imbalance resulting in the obesity 
epidemic. This is supported by the fact that during the same period dietary habits 
changed with increased portion sizes, changed meal composition and eating out, and 
the fact that palatable, energy-dense foods became readily available in our western 
society (5, 6, 8).  
The obesogenic environment cannot fully explain the development of obesity at 
an individual level, since there are still many individuals who manage to remain lean. 
This raises the question which factors determine the individual susceptibility to be-
come obese. Environmental factors, such as social, psychological, cultural or eco-
nomic status influence an individualsʼ behaviour and energy consumption patterns. In 
addition, there is evidence for a genetic predisposition to become obese (11). How-
ever, identifying genetic variants determining predisposition has been difficult. Gene-
gene interactions complicate the identification of genetic variants and the ones identi-
fied so far only explain a small fraction (12). An individual with a genetic predisposition 
is unlikely to develop obesity without being exposed to an obesity-promoting envi-
ronment, suggesting gene-environment interaction effects (13-17). Environment and 
genetics determine our physiology as well as our behaviour, which in turn determine 
energy intake and energy expenditure. This complex multi-layered network makes it 
difficult to elucidate the factors determining the individual susceptibility to become 
obese.  
Obesity and its co-morbidities like diabetes and cardiovascular disease can be 
reversed by weight loss. Weight loss through a negative energy balance is most 
commonly achieved by dieting. In the long-term, successful weight loss is uncommon. 
Successful long-term weight loss, defined as losing 10% of the initial body weight and 
maintaining the loss for at least 1 year, is only achieved in around 20% of the cases 
(18). Weight loss maintenance is counteracted by physiological adaptations in re-
sponse to weight loss. Increased feelings of hunger in response to weight loss make 
adherence to weight loss and weight maintenance diets difficult. The first part of this 
thesis encompasses food components that might help to reduce weight gain by de-
creasing the risk of overeating by suppressing appetite. The second part of this thesis 
encompasses factors involved in weight loss and weight maintenance thereafter. 
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Decreasing the risk of overeating 
Some food components might help to prevent weight gain or weight regain after 
weight loss by decreasing the risk of overeating. Potential effects are lowering portion 
size, decreasing meal frequencies and/or lowering the energy density of a meal. De-
creasing the risk of overeating might be accomplished by satiety-enhancing or appe-
tite-suppressing properties of food components. The first part of this thesis focuses on 
two potential appetite suppressing food components, namely oligofructose and 
Korean pine nut oil.  
A conceptual framework to examine the impact of food components on appetite is 
the satiety cascade (19). The cascade indicates a number of measurable targets, by 
linking physiological mechanisms to subjective feelings of appetite that determine 
appetite control (20). Potential mechanisms of appetite suppressing food components 
are slowing gastric emptying and the intestinal transit in order to promote satiety-
enhancing neuroendocrine feedback responses (21, 22). Potential appetite suppress-
ing food components are found to increase concentrations of the ʻsatietyʼ peptides 
glucagon like peptide-1 (GLP-1) and peptide YY (PYY), increase satiety feelings 
and/or reduce energy intake (23-32). However, results are inconsistent and often not 
sufficient to substantiate appetite-related claims (21). 
The inconsistent results might be a consequence of the large variation in study 
designs. Effectiveness of a food component depends among other things on the 
amount consumed. For many appetite suppressing food components, the minimal 
dosage necessary for establishing beneficial effects is still unknown, emphasizing the 
need to perform dose-response studies. Comparing studies is hampered by variation 
in methods used in these studies. Methods to determine an effect on energy intake 
varied from self-reported energy intake (30) to directly measuring energy intake by 
assessing consumption of an ad libitum meal (23, 26, 32). The timing of the meas-
urements is crucial and depends on the type and form, like solid or liquid, of the food 
component (33, 34). The supposed mechanism of action of the food component 
should be taken into account and piloting is essential for optimizing timing within a 
study design. To eventually support a health claim, an acute effect found in a short-
term study should be additionally tested in a long-term study to eliminate potential 
compensation (35). Furthermore, food components should be tested in a study popu-
lation resembling the intended users. Taken together, studies determining the effect of 
food components on appetite should be well designed, with thoroughly considering 
the dosage, timing of dosing regime, methods and study population.  
Factors involved in weight loss and weight maintenance thereafter 
Successful long-term weight loss is counteracted by homeostatic adaptations in re-
sponse to weight loss that create an elevated appetite and suppressed energy ex-
penditure promoting weight regain (36). Thus to prevent weight regain energy restric-
tion should be sustained. Some individuals manage to keep off the lost weight, while 
others regain all their lost weight. Like predisposition to develop overweight and 
obesity, individual susceptibility to successful weight loss and weight maintenance 
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seems to be determined by multiple factors. Genetic as well as behavioural and 
physiological factors shown to have a relationship with body weight might directly or 
indirectly affect weight loss and weight maintenance. Factors influence successful 
weight loss maintenance by changing in response to weight loss, thereby either re-
turning to a pre-obese state or favoring weight regain. The second part of this thesis 
encompasses factors involved in weight loss and weight maintenance thereafter, in 
particular genetic predisposition, adipose tissue metabolism and sleep. 
Genetic predisposition 
Despite the apparent dominant role of environmental factors in the obesity epidemic, 
genetic factors are known to affect the inter-individual susceptibility to develop 
obesity. Based on family and twin studies the genetic contribution is estimated at 40-
70% (11, 37). Since the start of the genome-wide association studies (GWAS), nu-
merous loci have been identified to be unequivocally associated with obesity related-
traits (12). However, the separate effects of these loci on obesity-susceptibility are 
small and explain only a small fraction of the total variation with a poor predictive 
ability (12, 38, 39). Studying GWAS-identified loci in longitudinal cohort studies can 
contribute to elucidating new physiological pathways that underlie obesity-
susceptibility. These studies are complicated since a large population size is needed 
and gene-gene and gene-environment interaction effects can mask the effect of a 
genetic variant (40).  
Longitudinal cohort studies already associated many genetic variants or single 
nucleotide polymorphisms (SNPs) with obesity, like polymorphisms in the fat mass 
and obesity associated (FTO) gene (41-46) and the melanocortin 4 receptor (MC4R) 
gene (47-49). Also individual differences in weight loss maintenance may in part be 
explained by a genetic predisposition to resist weight loss or to promote weight gain 
(50). Twin studies have demonstrated a much larger variability between pairs than 
within pairs on the response to long-term negative energy balance (51, 52). Some 
SNPs already associated with obesity might also be related to weight loss mainte-
nance. In this thesis the focus is on six SNPs that already showed associations with 
obesity-related traits and the possible association with weight loss maintenance. 
Adipose tissue metabolism 
Adipose tissue is a major energy-storing tissue, and an endocrine organ functionally 
responding to disturbances of energy balance. Under a negative energy balance, 
adipocytes will release fatty acids, whereas under a positive energy balance adipo-
cytes will actively take up and store fatty acids. Fat mass expansion is determined by 
both an increase in adipocyte size (hypertrophy) and number (hyperplasia) (53, 54). 
Metabolic disturbances associated with obesity, like insulin resistance, are typically 
associated with adipocyte hypertrophy (55), emphasizing the important role of adipose 
tissue in obesity. During weight loss, the decrease in fat mass results in a decrease in 
adipocyte size. Adipocyte metabolism is determined by adipocyte size, which reflects 
the amount of triacylglycerol stored in the adipocyte. In accordance with the link be-
tween adipocyte size and metabolism, metabolic processes in adipocytes of obese 
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subjects are dysregulated, and after weight loss either normalize to a pre-obese sta-
tus or change in favor of weight regain (56-60). Thus, changes in adipocyte glucose 
and fatty acid metabolism should be determined in relation to changes in adipocyte 
size during weight loss and maintenance. 
Sleep 
The increased prevalence of obesity coincides with a decrease in average sleep dur-
ation (61, 62). Epidemiological studies suggest that short sleep is a determinant of 
obesity (63, 64). A curvilinear relationship between sleep duration and body mass 
index (BMI) suggests that both short (<7hrs) and long (>8hrs) sleep have a negative 
effect on body weight (63, 65). Sleep deprivation results in a positive energy balance 
by disrupting the circadian rhythm, affecting physiological regulation mechanisms and 
behavioural factors (66, 67). However, the exact mechanisms by which sleep influen-
ces body weight need to be assessed and might involve both sides of the energy 
balance equation. Sleep deprivation can increase energy intake through alteration in 
the neuroendocrine control of appetite and reward (67-72). Short sleep duration can 
decrease energy expenditure by a decline in physical activity (73), or by an altered 
thermogenesis (74). In turn, it might be argued that the relationship between sleep 
duration and body weight is bi-directional. In addition to sleep influencing body weight, 
an increased body weight results in mechanical changes that increase work of breath-
ing, causing deteriorated sleep quality. Obese subjects are prone to develop sleep 
abnormalities like obstructive sleep apneu and sleep-disordered breathing (75). Since 
cause and effect cannot be disentangled the interpretation of results is complicated.  
Most studies on sleep were short or medium-term studies, where long-term stud-
ies are necessary to determine the relation between sleep and body weight changes 
during weight loss. During periods of energy restriction sufficient sleep contributes to 
the preservation of human fat-free body mass and an increase in sleep duration from 
a short to a healthier length was associated with an attenuation of fat mass gain (74, 
76). Therefore, to optimize success in weight loss and maintenance it is important to 
include sleep in the list of factors influencing body weight and assess the relationship 
between sleep duration and body weight. 
Outline of the thesis 
The research presented in the first part of this thesis is focussed on food components 
that might help to decrease the risk of overeating. Two types of potential appetite 
suppressing food components were tested in studies, in which the dosage, timing of 
dosing regime and methods were considered. The minimal dosage of oligofructose 
necessary for establishing beneficial long-term effects on the appetite profile, GLP-1 
and PYY concentrations and energy intake was determined in normal-weight and 
overweight men and women (chapter 2). Chapter 3 describes the effect of two 
dosages Korean pine nut oil on appetite ratings and energy intake at a previously 
determined sensitive moment in time.  
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The research presented in the second part of this thesis has a focus on factors 
involved in weight loss and weight maintenance. Chapter 4 describes a study in 
which it was examined whether body weight and short and long-term weight loss were 
affected by six candidate single nucleotide polymophisms (SNPs) and by changes in 
eating behaviour or by an interaction between these genetic and behavioural factors. 
Adipose tissue has a central role in the homeostatic adaptations in response to weight 
loss. As adipocyte size is a major modulator of endocrine functioning, methods allow-
ing accurate determination of adipocyte size are important in studying adipose tissue 
metabolism. In chapter 5 the relative shrinkage of adipocytes was assessed before 
and after weight loss by comparing adipose tissue from the same subjects embedded 
in paraffin and plastic. Thereafter changes in adipocyte glucose and fatty acid me-
tabolism were assessed in relation to adipocyte size during weight loss and mainte-
nance to determine whether metabolic processes in adipose tissue change in re-
sponse to weight loss either in line with a return to a pre-obese status or with favoring 
weight regain (chapter 6). Now, sleep is recognized as a determinant of obesity. 
Therefore, it is important to understand the temporal sequence of the relationship 
between sleep duration and changes in body weight and composition during short and 
long-term weight loss, which was assessed in the study described in chapter 7. 
Finally, the results of the above-described studies are summarized and discussed 
in chapter 8.  
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Abstract 
In rats oligofructose has been shown to stimulate satiety hormone secretion, reduce 
energy intake and promote weight loss. This study aimed to examine the effect of 
oligofructose supplementation on appetite profiles, satiety hormone concentrations 
and energy intake in humans. Thirty-one healthy subjects (10 men, 21 women) aged 
28±3 y with a BMI of 24.8±0.3 kg/m2 were included in a randomized double blind, 
crossover study. Subjects received 10g oligofructose, 16g oligofructose or 16g pla-
cebo (maltodextrin) daily for 13 days, with a 2-week washout period between the 
treatments. Appetite profile, active glucagon-like peptide 1 (GLP-1) and peptide YY3-
36 (PYY) concentrations and energy intake were assessed on day 0 and 13 of the 
treatment period. Time-by-treatment interaction revealed a trend for a reduction in 
energy intake over day 0-13 by oligofructose (p=0.068). Energy intake was signifi-
cantly reduced (11%) over time on day 13 compared to day 0 with 16g/d oligofructose 
(2801±301 vs. 3217±320 kJ, P<0.05). Moreover, energy intake was significantly lower 
with 16g/d compared with 10g/d oligofructose on day 13 (2801±301 vs. 3177±276 kJ, 
P<0.05). Area under the curve (AUC) for GLP-1 on day 13 was significantly higher 
with 16g/d compared to 10g/d oligofructose (45±4 vs. 41±3 pmol/Lxh, P<0.05). In the 
morning until the lunch AUC0-230min for PYY on day 13 was significantly higher with 
16g/d compared to 10g/d oligofructose and placebo (409±35 vs. 222±19 and 211±20 
pg/mlxh, P<0.01). In conclusion, 16 and not 10g/d oligofructose may be an effective 
dose to reduce energy intake, possibly supported by higher GLP-1 and PYY concen-
trations.  
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Introduction 
The prevalence of obesity has increased worldwide to epidemic proportions. Weight 
gain occurs when energy intake exceeds energy expenditure for a prolonged period of 
time. Therefore, novel foods that promote satiety and thereby reduce energy intake 
may be promising tools in weight management. A potential candidate ingredient for 
such foods is oligofructose, a fructan obtained as a partial enzymatic hydrolysate from 
chicory root inulin. It is fermented in the colon and it is especially known for its pre-
biotic effects and associated physiological effects (1-3).  
The hypothesis that oligofructose might have beneficial effects on energy intake is 
based upon rat studies (4, 5). In rats, energy intake was decreased over time in the 
animals fed with oligofructose compared to the animals fed with a control diet. This 
resulted in a decrease in epidydimal fat mass and visceral adipose tissue at the end of 
the treatment (6, 7). In addition, glucagon-like peptide-1 (GLP-1) amide and progluca-
gon mRNA concentrations were found to be higher in the oligofructose-fed rats (6, 7). 
GLP-1 is released from enteroendocrine L cells in response to nutrient ingestion. 
Fermentation of oligofructose into short-chain fatty acids (SCFA) in the gut has been 
shown to promote enteroendocrine L-cell differentiation in the proximal colon by up-
regulation of the differentiation factors (neurogenin 3 and NeuroD), thereby contribut-
ing to a higher endogenous GLP-1 production (8). GLP-1 was found to be essential in 
the control of food intake by oligofructose, since the beneficial effects of oligofructose 
were totally prevented in the presence of a GLP-1 receptor antagonist (9). In addition, 
GLP-1 receptor knockout mice (GLP-1R-/-) were completely insensitive to the actions 
of oligofructose (9).  
Although animal studies suggest that oligofructose may be a promising tool in the 
nutritional approach to controlling obesity, only a few studies have investigated the 
effect of oligofructose in humans. For instance plasma GLP-1 concentrations signifi-
cantly increased after oligofructose feeding of 20g/d for 7 days in patients with gastro 
esophageal reflux disease (10). It also has been demonstrated that inulin type-
fructans, added in food as fat-replacement, were able to lower energy intake (11). In a 
pilot study by Cani et al. (12), a two-week treatment with 16g/d oligofructose has been 
shown to promote satiety following breakfast and dinner, and to reduce hunger and 
prospective food consumption following dinner. Total energy intake per day was 5% 
lower during the oligofructose treatment than during the control treatment (12). These 
investigators also showed that with a different type of inulin consumption of 16g/d led 
to increased plasma levels of GLP-1 and PYY (13). Recently, a 12-week treatment 
with 21g/d oligofructose has been shown to increase the area under the curve (AUC) 
for the anorexigenic hormone peptide Y (PYY) and to decrease the AUC for the orexi-
genic hormone ghrelin (14). Self-reported energy intake was significantly lower in the 
oligofructose group and there was a reduction in body weight of about 1kg over 12 
weeks (14). 
However, information on the minimal dosage of oligofructose necessary for estab-
lishing beneficial effects is still lacking. Therefore, we performed a placebo-controlled 
crossover study to examine the effect of 10 and 16g/d oligofructose for 13 days on 
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appetite profile, GLP-1 and PYY concentrations and energy intake in normal weight 
and overweight men and women. 
Subjects and methods 
Subjects 
Thirty-one healthy subjects (10 men, 21 women) aged 20-60 y with a BMI of 23-
28 kg/m2 were recruited by advertisements in local newspapers and on notice boards 
at the university. Subjects underwent a screening and all were in good health, non-
smokers, not using medication (except for oral contraception) and moderate alcohol 
users. None of the subjects had a food allergy, gained or lost more than 5 kg in three 
months prior to the study, or were cognitive dietary restrained (F1 > 9) as assessed by 
a validated Dutch translation of the Three Factor Eating Questionnaire (TFEQ) (15). 
This study was conducted according to the guidelines laid down in the Declaration of 
Helsinki and all procedures involving human subjects were approved by the Central 
Committee on Human Research and by the Medical Ethical Committee of the Univer-
sity of Maastricht. Written informed consent was obtained from all subjects. 
Study design 
The study had a randomized, placebo-controlled crossover design. It consisted of 
three 13-day supplementation periods wherein oligofructose (Fructalose® L92, 10 or 
16g, Sensus, Roosendaal, The Netherlands) or placebo (maltodextrin, 16g) supple-
ments were consumed daily, separated by a 2-week washout period. Maltodextrin 
was selected as a placebo following previous studies on the effect of oligofructose 
(12, 14). Furthermore, maltodextrin has a similar taste and appearance as oligofruc-
tose. The supplements were provided in one-shot fruit drinks of 100 ml. Daily supple-
ments were divided into two equal portions of either 5 or 8 g, each to be consumed at 
home during breakfast and lunch. To determine the compliance, subjects kept the 
empty bottles and handed them in on later visits to the university. Potential adverse 
effects including flatulence, bloated feeling, abdominal rumbling and abdominal pain 
were monitored daily using a diary. Subjects were asked not to gain or lose weight 
consciously and to avoid pre- and probiotic foods as indicated on a provided list with 
food products. The subjects reported to the university six times at 0800h after an 
overnight fast on day 0 and 13 of each intervention interval. They were asked to ab-
stain from strenuous physical activity and alcohol, and not to eat or drink from 2200h 
the night before each test day. Energy intake and appetite profile ratings were deter-
mined on day 0 and 13. GLP-1 and PYY concentrations were determined on day 13.  
Study protocol 
On each test day subjectʼs body weight was measured with minimal clothing in the 
fasted state. Subjects received a standardized breakfast at 0830h consisting of 20% 
of the subjectʼs individual daily energy requirements. Subject-specific daily energy 
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requirements were derived from basal metabolic rate, which was calculated with the 
equation of Harris-Benedict (16). Basal metabolic rate was multiplied by an activity 
index of 1.5, as indicated for a sedentary day (17). Breakfast consisted of brown 
bread with cheese and marmalade, and fruit yogurt (21, 62 and 17 En% from respec-
tively protein, carbohydrate, fat). At 1230h subjects received a standardized lunch, 
which provided 40% of the subjectʼs individual daily energy requirements. The lunch 
consisted of brown bread with egg and tuna sandwich salad, tomato soup and grape 
juice (18, 55 and 27 En% from respectively protein, carbohydrate, fat). Food and en-
ergy intake were assessed on day 0 and 13 via an ad libitum dinner at 1700h, which 
consisted of a homogeneous hot pasta meal. The dinner was weighed before and 
after eating. Subjects were instructed to eat till they were comfortably full. The lasagna 
(1350g) provided 5 kJ/g (31, 45 and 24 En% from respectively protein, carbohydrate, 
fat). Appetite profile ratings were measured 16 times with regular intervals between 
0830 and 2000h on day 0 and 13. On day 13, nine blood samples were collected at 
0820, 0900, 0930, 1030, 1220, 1300, 1330, 1430 and 1530h, respectively in order to 
obtain GLP-1 and PYY concentrations over the day.  
Appetite profile 
Appetite profile ratings were evaluated using anchored 100-mm visual analogue 
scales (VAS) (18, 19). Hunger, fullness, satiety, thirst, desire to eat and prospective 
food consumption were measured. The scale was anchored from ʻnot at allʼ on the left 
to ʻextremelyʼ on the right. Participants were instructed to rate their feelings by mark-
ing the scale with a vertical line at the point that was most appropriate at that time. 
The distance from the left end of the scale to this vertical line on the scale was meas-
ured in mm; changes from baseline were calculated by subtracting the baseline score 
from the score at a certain time point. On each test day these questionnaires were 
completed at 0830, 0900, 0930, 1030, 1130, 1230, 1300, 1330, 1430, 1530h, 1630, 
1700, 1730, 1800, 1900 and 2000h. 
Blood sampling 
On day 0 and day 13 a catheter was placed into the antecubital vein for blood sam-
pling. Blood samples were collected in tubes containing EDTA, 10µl DPPIV per ml 
blood and 50µl aprotonin per ml blood for measurements of PYY concentrations. For 
GLP-1 measurements, blood was collected in EDTA tubes containing 10µl DPPIV per 
ml blood.  Plasma was obtained by centrifugation (4°C, 1000 × g, 10 min) and stored 
at -80°C until analyzed. PYY3-36 concentrations were measured with a specific and 
sensitive radioimmunoassay (Linco Research Inc., St Charles, MO, USA). Plasma 
active GLP-1 concentrations were measured by enzyme-linked immunoradiometric 
assay (EGLP-35K; Linco Research Inc., St Charles, MO, USA). 
Statistical analysis 
Data are presented as mean changes from baseline and their standard errors, unless 
otherwise indicated. Area under the curve (AUC) of changes from baseline over time 
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was calculated by using the trapezoid method. A studentʼs t test (two-tailed distribu-
tion) was carried out to determine possible differences between the conditions. 
ANOVA repeated measures was carried out with a repeated covariance structure to 
determine possible differences in appetite ratings and energy intake between condi-
tions, and time-by-treatment interactions. Significance was defined as P<0.05. All of 
the statistical analyses were executed with SPSS version 16.0 for Macintosh OS X 
(SPSS Inc, Chicago, IL). 
Results 
Subject characteristics 
Two subjects dropped out because of personal reasons. Twenty-nine subjects (9 
men, 20 women) completed the study. The baseline characteristics of these subjects 
are presented in table 1. As expected, body weight and height were significantly dif-
ferent between men and women. Body weight did not change over time and there 
were no significant differences in body weight between the conditions. Moreover, no 
sex differences were present with respect to changes in measured variables, so the 
whole group was analyzed together. 
 
 
Table 1: Subject characteristics (mean ± SEM) 
 N=29 Men (n=9) Women (n=20) 
Age (y) 28 ± 3 32 ± 6 26 ± 3 
Height (m) 1.73 ± 0.02 1.80 ± 0.03 1.70 ± 0.023 
Body Weight (kg) 74.7 ± 2.0 83.1 ± 3.8 70.9 ± 1.83 
BMI1 (kg/m2) 24.8 ± 0.3 25.5 ± 0.6 24.5 ± 0.4 
Dietary restraint2 6.0 ± 0.6 4.8 ± 1.0  6.2 ± 0.7 
1BMI = Body Mass Index 
2Dietary restraint = Factor 1 of the Three-Factor Eating Questionnaire (15) 
3 Significantly different from men, P<0.01 (ANOVA)  
 
Appetite profile 
On day 0 AUC for appetite profile ratings was not significantly different between the 
three conditions. No time x treatment differences were present with respect to the 
appetite profile ratings. 
PYY and GLP-1 
Fasting PYY concentrations, but not fasting GLP-1 concentrations were significantly 
lower on day 13 compared to day 0 in all conditions (49.9±4.4 vs 71.2±3.9 pg/mL for 
placebo, 46.9±4.6 vs 71.9±3.6 pg/mL for 10g/d oligofructose and 53.8±4.7 vs 
74.1±3.9 pg/mL for 16g/d oligofructose, P<0.01).  
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After the meals, PYY concentrations significantly increased in all conditions (fig-
ure 1A-B, P<0.05). In the morning until the lunch AUC0-230min for PYY was signifi-
cantly higher with 16g/d oligofructose than with 10g/d oligofructose and placebo 
(409±35 vs 222±19 and 211±20 pg/mLxh, P<0.01). This gradually diminished over the 
day, resulting in a trend for a larger total AUC for PYY with 16g/d than with 10g/d 
oligofructose or placebo (P = 0.065). 
After the meals, GLP-1 concentrations also increased significantly in all conditions 
(figure 1C-D P<0.05). AUC for GLP-1 was significantly higher with 16g/d oligofructose 
compared to 10g/d oligofructose (P<0.05). In addition, AUC for GLP-1 with 10g/d 
oligofructose was significantly lower compared to placebo (P<0.05). 
Compliance and side effects 
Compliance was high, as shown by the empty packages returned at the end of each 
treatment. Incidentally subjects returned a full package, indicating a missed dose. The 
subjects also reported this in their diary, showing that missing doses remained below 
5%. Only a small proportion of these missing doses was on the day prior to the meas-
urements, and no doses were missed on the day of the measurements. 
Adverse effects, like flatulence, abdominal rumbling, bloated feeling and cramps 
were significantly higher for 10 and 16g/d oligofructose compared to placebo at sev-
eral days during the treatment, respectively (P < 0.05, data not shown). However, 
none of the subjects did complain about side effects and there were no significant 
time-by treatment interactions. Also, side effects did not influence compliance, since 
compliance was similar in the placebo treatment as with 10 and 16g/d oligofructose. 
Energy intake 
On day 0, energy intake during the ad libitum dinner was similar for all the conditions 
(2788±251, 3127±267 and 3217±321 kJ for respectively placebo, 10g/d and 16g/d 
oligofructose). Subsequently, energy intake was significantly lower on day 13 after the 
16g/d oligofructose teatment (11%, p<0.05) compared to 10g/d oligofructose 
(2801±301 vs. 3177±276 kJ, P<0.05, figure 2), but not compared to placebo 
(2979±276 kJ). 
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Figure 1. Mean (± SEM) values for plasma (A) peptide YY3-36 (PYY; time-by-treatment interac-
tion P=0.065), and (B) active glucagon-like peptide 1 (GLP-1; time-by-treatment interaction 
P=0.041) concentrations during day 13 as absolute concentrations (pg/mL, pmol/L) with break-
fast consumed at 10 min and lunch at 250 min, area under the curve (AUC) for (C) PYY3-36 and 
(D) active GLP-1 (pg/mmlxh, pmol/Lxh). 16g/d oligofructose (, black), 10g/d oligofructose (, 
grey) and placebo (∆, white). * Significant difference between 16g/d oligofructose and 10g/d 
oligofructose, P<0.05; + significant difference between 16g/d oligofructose and placebo, P<0.05; 
# significant difference between 10g/d oligofructose and placebo, P<0.05; § significant difference 
between 10g/d oligofructose and 16g/d oligofructose and placebo, P<0.05 (ANOVA repeated 
measures). 
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Figure 2. Changes in energy intake (kJ) between day 0 and 13 after placebo, 10g/d oligofructose 
and 16g/d oligofructose treatment. Time-by-treatment interaction P=0.068 # significant difference 
between the conditions, * significantly different from baseline, P < 0.05 (ANOVA repeated-
measures). 
Discussion 
In this study the effect of oligofructose supplementation on appetite profiles, satiety 
hormone concentrations and energy intake in humans was examined. Energy intake 
decreased over time with 16g/d oligofructose, whereas consumption of 10g/d 
oligofructose did not change energy intake. There were no significant associations of 
the oligofructose-induced reduction in energy intake with appetite profile ratings. 
Reduced energy intake on day 13, with 16g/d oligofructose was underscored by 
higher AUC0-230min of PYY hormone concentrations with 16g/d compared to 10g/d 
oligofructose and placebo, and higher AUCtotal of GLP-1 hormone concentrations with 
16g/d compared to 10g/d oligofructose, although not significantly different from pla-
cebo. Based on rat studies (6, 9, 7), it is suggested that oligofructose intake results in 
increased GLP-1 and PYY concentrations mediated via the SCFA, which are pro-
duced by the fermentation of oligofructose. Previous studies in humans showed an 
increased AUC for PYY with 21g/d oligofructose, whereas GLP-1 did not change (14). 
Moreover, fasting PYY concentrations on day 13 compared to day 0 were decreased 
in all conditions, suggesting an effect not specifically due to oligofructose consump-
tion. However, the subjects may have experienced a different feedback of SCFA from 
the colon due to consumption of a different macronutrient and particularly fiber com-
position in general, resulting in an overall reduction of PYY. 
The results on appetite profile ratings suggest that oligofructose does not sup-
press appetite. This is not consistent with previous findings (12). On the other hand, 
Archer et al. (11) could not find an effect for inulin on appetite at a lower dosage, but 
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they did find a decrease in energy intake. However, differences in study design, such 
as standardized meals versus ad libitum and free choice meals, and differences in 
population size and type of inulin used complicate comparison between studies. In 
addition, measuring subjective appetite ratings with VAS can result in high variability 
(18, 19). Probably, oligofructose does not affect appetite feelings sufficiently to be 
detected with the use of VAS. 
Observations on side effects as reported in the literature are not consistent. Sev-
eral measurement methods are used, like diaries, questionnaires with 4-point scale 
(20) or VAS questionnaires (14). In addition, some studies report about side effects 
without explaining measurement procedures (12), or do not report about side effects 
at all (11). This makes it difficult to compare results between studies. We combined 
the VAS questionnaires with diaries to analyze occurrence of side effects over time. 
Consumption of 10 and 16g oligofructose daily for 2 weeks did result in minor gastro-
intestinal side effects. However, no subjects complained, compliance was not affected 
by the side effects, and we did not observe a relation of side effects with energy in-
take.  
The observed reduction of energy intake induced by 16g/d oligofructose over a 
time interval of 13 days is in agreement with earlier findings (12, 14). However, differ-
ences between 16g/d oligofructose and placebo were not significant. Since the pla-
cebo is a polysaccharide, there might be an effect of 16g/d maltodextrin itself on en-
ergy intake, through which the differences between placebo and 16g/d oligofructose 
become too small in order to reach significance. Maltodextrin, in higher concentrations 
(62.9g), has been shown to lower energy intake (21). 
Energy intake did not change with 10g/d oligofructose. This suggests that only 
16g/d oligofructose is a minimal dosage to induce an effect of oligofructose on energy 
intake. Our results suggest that oligofructose-induced reduction in energy intake might 
be exerted via increased GLP-1 and PYY concentrations.  
A limitation of this study is the nature of the treatment. With such a minimum 
dosage, i.e. 16g/d as compared to 21g/d in other studies, the study needs more sensi-
tivity. A larger number of subjects and a longer period of time may have shown more 
robust results. However, we found for consumption of 16g/d oligofructose a trend for a 
time-by-treatment effect over 13 days, as well as lower energy intakes at the final day 
of treatment. The latter was supported by higher AUC concentrations of GLP-1 and for 
PYY in the morning. Another limitation of this study is that we did not measure SCFA. 
Although measuring SCFA in vivo in humans is challenging, combining SCFA meas-
urements in both faeces and blood could contribute to explaining the mechanism 
behind the effect of oligofructose on energy intake.  
In conclusion, 16 and not 10g/d oligofructose may be an effective dose to reduce 
energy intake in normal weight and overweight men and women, underscored by 
elevated GLP-1 and PYY concentrations.   
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Abstract 
Triacylglycerols (TAG) have been shown to have potential appetite suppressing ef-
fects. This study examined the effects of 3g and 6g Korean pine nut triacylglycerols 
(PinnoThin) on appetite and energy intake. 130g Isoenergetic yogurt containing either 
placebo (milk fat) or PinnoThin TAG was consumed as a breakfast, after an overnight 
fast, in a double blind randomized crossover design. Appetite profile ratings were 
determined by visual analogue scale at regular intervals for a period of 4h after the 
breakfast. In phase I, 6g PinnoThin TAG and placebo was tested in thirty-three heal-
thy women (mean±SD, BMI 26.4±3.8 kg/m2; age 28±10 y) to determine the appetite 
suppressing effect in time. In phase II, an additional dose of 3g PinnoThin TAG, as 
well as 6g PinnoThin TAG and placebo, was tested in thirty-four women (BMI 
25.8±2.9 kg/m2; age 25±9 y) to determine energy intake from an ad libitum lunch 
offered at 210 min after the breakfast, at which maximal differences in appetite profile 
ratings were present in phase I. Area under the curve of appetite profile ratings was 
not significantly different between the conditions. Energy intake was 9.5% lower after 
6g PinnoThin TAG compared with 3g PinnoThin TAG, but there was no significant 
difference with the placebo. To conclude, a dosage of 6g PinnoThin TAG is not suffi-
cient to suppress appetite and energy intake. 
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Introduction 
An effective strategy to prevent the positive energy balance resulting in obesity is still 
lacking. It has been shown that a positive energy balance of 50 kcal per day already 
results in an increase in body weight of at least one kilo per year (1). A potential pre-
vention strategy is by reducing food intake via the use of (natural) appetite suppress-
ants. 
Different macronutrients exert various postprandial effects and stimulate the re-
lease of satiety hormones to different degrees. Fat intake is known to induce the re-
lease of gastro-intestinal hormones, like cholecystokinin (CCK) and glucagon-like 
peptide-1 (GLP-1). Both CCK and GLP-1 have shown to be involved in the develop-
ment of satiation, by suppressing appetite and energy intake (2-5). The satiating effect 
of fat is influenced by chain length and the degree of saturation of the fatty acids. Only 
fatty acids with chain lengths ≥ C12 are capable of reducing food intake and releasing 
CCK and GLP-1 (6, 7). Furthermore, long-chain fatty acids have been shown to be 
more effective than medium-chain fatty acids (8, 9). Regarding the degree of satura-
tion, it has been shown that polyunsaturated fatty acids (PUFAs) have a more potent 
effect on reducing food intake and increasing the release of satiety hormones than 
monounsaturated fatty acids (MUFAs) (8). 
PinnoThin is an oil from Korean pine nuts (Pinus Koraiensis) which consists of 
66% polyunsaturated fatty acids (PUFAs; linoleic (C18:2) and pinolenic acid (C18:3)) 
and 26% monounsaturated fatty acids (MUFAs; oleic acid (C18:1)) (10). The large 
amounts of PUFAs in PinnoThin suggest that PinnoThin might be able to reduce ap-
petite by the induction of satiety hormones.  
Previous studies have shown that PinnoThin triacylglycerol (TAG) and free fatty 
acids (FFA) can produce an increase in CCK and GLP-1 release in post-menopausal 
overweight women (11). AUC of appetite ratings were not significantly different after 
the consumption of PinnoThin (FFA and TAG) (11), probably because the study was 
underpowered with only 18 overweight postmenopausal women. Moreover, observa-
tions were not corrected for baseline measurements, leading to the question whether 
the results were based upon clear statistically significant differences between treat-
ment and placebo. No effects of PinnoThin TAG on appetite ratings were found in a 
study with 42 overweight women (12). In contrast, in the same study 2 g PinnoThin 
FFA resulted in a trend for reduced energy intake (7% reduction, P=0.09) (12). The 
authors suggest that the lack of an effect of PinnoThin TAG could be attributed to the 
timing of the dosing regime. Absorption of fatty acids in the gut from TAG is slower 
compared to FFA, consequently the time between consumption of PinnoThin TAG and 
the ad libitum lunch (30 min) was probably too short to detect an effect. 
The present study was designed to measure the effect of PinnoThin TAG (66% 
PUFAs and 26% MUFAs), in a sufficient number of subjects. In a first phase, the 
effect of PinnoThin TAG on appetite ratings was evaluated. To overcome the problem 
of timing of the dosing regime we determined the sensitive moment in time, at which 
maximal differences between one dosage of PinnoThin TAG and placebo in appetite 
profile ratings were present, in this first phase. In a second phase, the effect of two 
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dosages of PinnoThin TAG vs. placebo on energy intake at this previously determined 
relevant time point was evaluated to determine the minimum effective dosage.  
Subjects and methods 
Subjects 
Thirty-nine healthy women aged 18-45 y with a BMI of 23-30 kg/m2 were recruited by 
advertisements in local newspapers and on notice boards at the university. All sub-
jects underwent a screening and were in good health, regularly consuming breakfast, 
nonsmokers, not using medication (except for oral contraception) and at most moder-
ate alcohol users. None of the subjects had a food allergy, had gained or lost more 
than 5 kg in three months prior to the study, or were cognitively dietary restrained (F1 
> 13) as assessed by a validated Dutch translation of the Three Factor Eating Ques-
tionnaire (TFEQ) (13). This study was conducted according to the guidelines laid 
down in the Declaration of Helsinki and all procedures involving human subjects were 
approved by the Central Committee on Human Research and by the Medical Ethical 
Committee of the University of Maastricht. Written informed consent was obtained 
from all subjects. 
Study protocol 
The study had a double blind, randomized, crossover design. Test day were sched-
uled in the same phase of the subjectsʼ menstrual cycle, at least one menstrual cycle 
apart. Subjects were provided with a meal to consume at home on the evening prior to 
each test day. They were asked to abstain from strenuous physical activity and not to 
eat or drink from 2200h the night before the test day. The subjects reported to the 
university at 0845h after an overnight fast. At 0900h the subjects received a yogurt 
breakfast (130g) containing either PinnoThin TAG or placebo (milk fat).  
The study consisted of two phases, with the results of phase I determining the 
timing of the measurement in phase II. During phase I, appetite ratings were deter-
mined at regular intervals for a period of 4h after the test breakfast with 6 g PinnoThin 
TAG or 6 g placebo. In phase II, an ad libitum lunch was offered at the previously 
determined sensitive moment in time, based on the maximal differences in appetite 
profile ratings in phase I. In addition to 6 g PinnoThin TAG and 6 g placebo, an extra 
dose of 3 g PinnoThin TAG was tested with a yogurt breakfast containing a mixture of 
3 g PinnoThin TAG and 3 g milk fat.  
Appetite ratings 
Appetite was evaluated using anchored 100-mm visual analogue scales (VAS) in both 
phase I and II (14, 15). Hunger, fullness, satiety, thirst, desire to eat, prospective food 
consumption and nausea were assessed. The scale was anchored from ʻnot at allʼ on 
the left to ʻextremelyʼ on the right. On each test day, these questionnaires were com-
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pleted before breakfast at 0855h, after breakfast at 0915 and 0930h and every 30 
minutes thereafter (1000, 1030, 1100, 1130, 1200, 1230 and 1300h). 
Yogurt breakfast 
Breakfast was a yogurt (130 g) containing either 6 g milk fat, 3 g PinnoThin TAG and 
3 g milk fat or 6 g PinnoThin TAG, which provided 46, 11 and 43 En% from carbohyd-
rate, protein and fat respectively. The energy content of the breakfast was 523kJ. 
PinnoThin TAG consists of 66% polyunsaturated fatty acids (PUFAs; linoleic (C18:2) 
and pinolenic acid (C18:3)) and 26% monounsaturated fatty acids (MUFAs). The 
subjects were instructed to consume the yogurt within 5 minutes and to hold each 
spoon of yogurt in their mouth for 5-10 seconds before swallowing. 
The yogurts were produced by NIZO Food Research b.v. (Ede, The Netherlands) 
with either PinnoThin TAG (Lipid Nutrition b.v., Wormerveer, The Netherlands) or milk 
fat (Corman b.v., Goé, Belgium) and were flavored with a mixture of orange, apple 
(SVZ, Breda, The Netherlands), lemon and passion fruit (Givaudan b.v., Barneveld, 
The Netherlands). The yogurts did not differ in color, flavour or viscosity.  
Energy intake 
Food and energy intake were determined using an ad libitum lunch in phase II. Lunch 
consisted of Turkish bread (330g) with egg salad (600g) and was weighed before and 
after eating. Subjects were instructed to eat till they were comfortably full. The lunch 
had an energy density of 11.5kJ/g with 44, 17 and 39 En% from carbohydrate, protein 
and fat respectively.   
Statistical analysis 
Since baseline values did not differ, data are presented as mean changes from base-
line and their standard errors, unless otherwise indicated. The area under the curve 
(AUC) of changes from baseline over time (4h for appetite ratings) was calculated 
using the trapezoid method. A repeated-measures ANOVA was carried out to deter-
mine possible differences in appetite ratings and energy intake between the Pin-
noThin TAG (3 g and 6 g) and placebo breakfast. Significance was defined as P<0.05, 
unless otherwise indicated. A power calculation was performed to determine the num-
ber of subjects required and was based on a difference in food intake after intake of 
2g PinnoThin FFA observed in a previous study (12). With an observed difference of 
7% and a standard deviation of 10%, it was calculated that after taking a 15% dropout 
into account 30 subjects were needed to achieve sufficient power (90%) to observe 
significant (P<0.05) changes in food intake as a result of the treatment. All of the stat-
istical analyses were executed with SPSS version 16.0 for Macintosh OS X (SPSS 
Inc, Chicago, IL). 
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Results  
Subject characteristics 
Thirty-three women participated in phase I. Five women of this group did not partici-
pate in phase II, because of personal reasons and/or lack of time. Six new female 
subjects were recruited for phase II, and together with the remaining 28, a total of 34 
women completed the second set of experiments. Subject characteristics of both 
phases are presented in table 1. 
 
Table 1: Subject characteristics (mean ± SEM) 
 Phase I Phase II 
 33 women 34 women* 
Age (y) 28 ± 2 25 ± 2 
Height (m) 1.69 ± 0.01 1.70 ± 0.01 
Body Weight (kg) 75.6 ± 1.9 74.3 ± 1.7 
BMI (kg/m2) 26.4 ± 0.4 25.8 ± 0.5 
Dietary restraint** 7.1 ± 0.7 6.5 ± 0.7 
BMI = Body Mass Index 
*28 subjects completed both phases. Five women dropped out before phase II was completed 
and therefore six new subjects were recruited for phase II. 
**Dietary restraint = Factor 1 score of the Three-Factor Eating Questionnaire (13) 
Phase I 
Hunger ratings were significantly decreased after 6 g PinnoThin TAG compared with 
placebo at 210 min after the breakfast (6 (SEM 4) v. 14 (SEM 4) mm VAS; P < 0.05; 
figure 1a). Prospective food consumption was decreased after PinnoThin TAG com-
pared to placebo at 210 min after the breakfast (0 (SEM 4) v. 8 (SEM 3) mm VAS; P < 
0.05; figure 1e). The time-by-treatment interaction did not reach significance and the 
AUC for the appetite ratings was not significantly different between the treatments. 
Based on these results, in phase II an ad libitum lunch was offered at 210 min after 
breakfast with placebo, 3 g or 6 g PinnoThin TAG. 
Phase II 
The time-by-treatment interaction did not reach significance and also the AUC for the 
appetite ratings was not significantly different between the treatments. Appetite ratings 
over time were comparable between phase I and II. 
Energy intake was decreased significantly by 9.5% after the breakfast with 6 g 
PinnoThin TAG compared with the breakfast with 3 g PinnoThin TAG (P<0.05; table 
2). The lowered energy intake after 6 g PinnoThin TAG did not reach significance 
compared with the placebo. In addition, there was no significant difference between 
energy intake after 3 g PinnoThin TAG and placebo. These results remain similar after 
correcting energy intake for body weight, height and age of each subject. This was 
done by defining energy intake as a % of energy requirement (ER), calculated accord-
ing to the Harris-Benedict equations, multiplied by an activity index of 1.7 (16).   
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Figure 1. Changes in hunger (A), satiety (B), fullness (C), desire to eat (D) and prospective food 
consumption (E) (all in mm visual analogue scale; VAS) over time (min) after a yogurt breakfast 
with either placebo (∆) or 6g PinnoThin TAG () expressed as changes from baseline in 33 
women (phase I). Values are means, with standard errors represented by vertical bars. *P<0.05 
with repeated-measures ANOVA. 
 
 
 
Ratings of liking of the yogurt breakfast, nausea and thirst were not different be-
tween the treatments. Nausea ratings were extremely low and changes from baseline 
over time did not become positive. No adverse events were reported. 
 
 
Table 2. Food (gram) and energy (kJ) measured with an ad libitum lunch 210 min after a break-
fast with placebo, 3 g and 6 g PinnoThin TAG in 34 women in phase II (mean ± SEM) 
 Placebo 3g TAG 6g TAG 
Food intake (gram) 312 ± 13 327 ± 11 296 ± 11* 
Energy intake (kJ) 3594 ± 150 3766 ± 134 3409 ± 130* 
*Significant different from 3 g PinnoThin: P<0.05 (repeated-measures ANOVA). 
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Discussion  
The time-by-treatment interaction and differences in AUC for the appetite ratings were 
not significant in both phases. Energy intake was reduced by 9.5% after supplementa-
tion of 6 g PinnoThin TAG compared with 3 g PinnoThin TAG. However, the reduction 
in energy intake after 6 g PinnoThin TAG when compared with placebo did not reach 
significance. 
If PinnoThin TAG indeed acts as an appetite suppressant, it would be expected 
that PinnoThin TAG suppresses appetite measured via appetite profile ratings with 
VAS. However, the time-by-treatment interaction was not significant. In the study of 
Hughes et al. (12), there were also no effects of 6 g PinnoThin TAG on appetite rat-
ings, and in the study of Pasman et al. (11) PinnoThin TAG only marginally affected 
appetite ratings. These studies had major differences between the study protocols. 
For example, PinnoThin was consumed 3.5 h after the breakfast in the Hughes study, 
instead of simultaneously with a breakfast after an overnight fast in this study, as well 
as the Pasman study. Previous studies supplemented PinnoThin in a capsule (11, 
12), whereas in this study PinnoThin TAG was incorporated in a yogurt breakfast. 
Also, milk fat instead of olive oil was used as a placebo in this study. In addition, the 
Pasman study was underpowered with only 18 postmenopausal overweight women 
(11). Our sample size was sufficiently large to reach power.  
Differences between FFA and TAG also cause the contradictory results in the lit-
erature. FFAs have a stronger effect on CCK release, fullness and hunger ratings and 
energy intake compared with TAGs (17). FFAs can directly exert effects in the gut, 
whereas FFAs from TAGs are released during intestinal lipolysis. In the Hughes study 
food intake (grams), and not energy intake (kJ), was reduced during an ad libitum 
lunch 30 min after supplementation of 2 g FFA, while PinnoThin TAG did not have an 
effect on food nor energy intake (12). It has been suggested that the short amount of 
time between PinnoThin TAG supplementation and the ad libitum lunch can explain 
the absence of an effect on energy intake in Hughes study (12). The rate of small 
intestinal lipolysis of TAGs is unknown, and seems to depend on several factors (17), 
like the rate of pancreatic lipase secretion and also the rate of entry of TAGs into the 
duodenum. In turn, the latter depends on the rate of gastric emptying, which varies 
with the amount and physical properties of the meal (18). Therefore, the concentration 
of FFA required in the intestine to suppress energy intake is still unclear (17). Fur-
thermore, only two out of three fatty acids will become available from TAG. This sug-
gests that a same dosage of FFA would elicit a stronger effect on energy intake com-
pared with TAG. To get around these unknown variables we optimized the measure-
ments by determining energy intake at a previous determined sensitive moment in 
time, at which maximal differences in appetite profile ratings were present. However, 
the reduction in energy intake after 6 g PinnoThin TAG when compared with placebo 
did not reach significance. The observed effects of PinnoThin TAG may become 
stronger when a higher dose is supplemented. However, a higher dose is not desir-
able for physiological and industrial reasons. With PinnoThin TAG being a fat, a 
higher dose might not result in a net reduction of total daily fat intake. Furthermore, 
the acute effects of a single dose of PinnoThin TAG could be different from the effects 
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after a long-term trial, but no studies thus far have investigated the effect of PinnoThin 
TAG in the long term. 
In this study, unlike earlier studies, the effect of 2 dosages PinnoThin TAG on en-
ergy intake is determined at a previously determined sensitive moment in time, in a 
sufficiently large number of subjects to reach power (to detect an effect size of 7% 
with a power of 90% at P=0.05). Although no appetite suppressing effect of PinnoThin 
TAG is found in the concentrations used in this study, the results significantly contri-
bute to the field of research on potential appetite suppressants. Clearly, a lowest 
dosage as possible is preferred for physiological as well as industrial reasons. In 
order to find a minimum effective dosage it is important to perform studies with several 
dosages. Further studies need to be done to determine whether higher concentrations 
of PinnoThin TAG do have an appetite suppressing effect. From these results we 
conclude that a dosage of 6 g PinnoThin TAG is not sufficient to suppress appetite 
sensations and energy intake.  
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Abstract 
Interindividual differences in response to weight loss and maintenance thereafter are 
ascribed to genetic predisposition and behavioural changes. To examine whether 
body weight and short and long-term body weight loss were affected by candidate 
single nucleotide polymophisms (SNPs) and changes in eating behaviour or by an 
interaction between these genetic and behavioural factors. 150 healthy subjects (39 
males, 111 females) aged 20-50 y with a BMI of 27-38 kg/m2 followed a very low 
energy diet for 8-weeks, followed by a 3-month weight maintenance period. SNPs 
were selected from six candidate genes: ADRB2, FTO, MC4R, PPARG, PPARD, and 
PPARGC1A. Changes in eating behaviour were determined with the Three Factor 
Eating Questionnaire. A high genetic predisposition score was associated with a high 
body weight at baseline and more short-term weight loss. From the six selected obesi-
ty-related SNPs, FTO was associated with increased body weight at baseline, and the 
effect allele of PPARGC1A was positively associated with short-term weight loss, 
when assessed for each SNP separately. Long-term weight loss was associated with 
a larger increase in dietary restraint and larger decrease in disinhibition. During long-
term weight loss, genetic effects are dominated by changes in eating behaviour. 
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Introduction 
Obesity results from a chronic imbalance between energy intake and expenditure [1]. 
The increasing prevalence of obesity coincides with changes in dietary habits due to 
high availability of energy-dense foods, suggesting a causal link [2]. However, some 
individuals seem resistant to become overweight or obese. Inter-individual variation in 
the susceptibility to develop obesity can be partly explained by genetics. Family and 
twin studies have shown that the genetic contribution can be 40-70% [3, 4]. Genome-
wide association studies (GWAS), already identified 52 genetic loci to be unequivo-
cally associated with obesity related-traits [5]. However, the effects of the loci on obe-
sity-susceptibility are small and explain only a small fraction of the total variation with 
a poor predictive ability [5-7]. Studying the GWAS-identified loci in longitudinal cohort 
studies can contribute to elucidating new physiological pathways that underlie obesity-
susceptibility. 
Most association studies focus on single nucleotide polymorphisms (SNPs) in re-
lation to body weight, instead of changes in body weight. Successfully maintaining 
weight loss, defined as “keeping off an intentional loss of at least 10% body weight for 
at least one year” is only achieved in around 20% of the cases [8, 9]. Individual differ-
ences in weight loss and regain may in part be caused by a genetic predisposition to 
resist weight loss or promoting weight gain [10]. Twin studies on the response to long-
term negative energy balance have demonstrated a much larger variability between 
pairs than within pairs [11, 12], suggesting that there is also a genetic contribution in 
the resistance for body weight loss and maintenance.   
In this study, we tested the combined and individual effect of six genetic variants, 
which had shown associations with obesity-related traits: rs9939609 of fat mass and 
obesity associated (FTO) gene; rs17782313 of melanocortin 4 receptor (MC4R) gene; 
rs1042713 of β2-adrenergic receptor (ADRB2) gene; rs1801282 of peroxisome prolif-
erator-activated receptorγ2 (PPARγ2) gene; rs8192678 of peroxisome proliferator-
activated receptorγ coactivator-1α (PPARGC1α) gene; rs2076168 of peroxisome 
proliferator-activated receptorδ (PPARδ) gene. The aim of the study was to examine 
whether body weight changes during an 8-week weight loss period and subsequent 
follow-up of 3-months were affected by the six selected SNPs and by changes in 
eating behaviour, or by an interaction between these genetic and behavioural factors. 
Material and methods 
Subjects 
150 healthy subjects (39 males, 111 females) aged 20-50 y with a BMI of 27-38 kg/m2 
participated in the study, which started in February 2010. The weight loss diet consi-
sted of 8 weeks very low energy diet providing 2.1 MJ/day (Modifast; Nutrition et San-
té Benelux, Breda, The Netherlands). This diet was a protein-enriched formula diet 
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that provided 50g carbohydrates, 52g protein, 7g fat and a micronutrient content, 
which meets the Dutch recommended daily allowance. Vegetables were allowed in 
addition to the diet. The weight loss period was followed by a weight maintenance 
period of 3 months, in which subjects were instructed to maintain their newly achieved 
body weight. Measurements were done at rest and following an overnight fast at three 
time points; before weight loss, after weight loss and after 3 months follow-up. The 
study was conducted according to the guidelines laid down in the Declaration of Hel-
sinki and all procedures involving human subjects were approved by the Central 
Committee on Human Research and by the Medical Ethical Committee of Maastricht 
University. Written informed consent was obtained from all subjects. The study was 
registered in ClinicalTrials.gov (registration number: NCT01015508). 
Anthropometry 
Height was measured at screening to the nearest 0.1cm with the use of a wall-
mounted stadiometer (model 220; Seca, Hamburg, Germany). Body weight was mea-
sured with subjects in underwear after an overnight fast using a calibrated scale of the 
BodPod. Body mass index (BMI) was calculated by dividing body weight by height 
squared (kg/m2).  
Body composition was calculated from body volume (BodPod, Life measure-
ment, Concord, CA, USA) [13] and total body water (TBW) [14] as assessed with the 
deuterium dilution technique, using Siriʼs three-compartment model [15]. The dilution 
of the deuterium isotope (2H2O) is a measure for total body water. Subjects wore tight-
ly fitting bathing suits and a swim cap during the volume-measurements in the Bod-
Pod, and had not engaged in exercise at least 1 hour prior to the test.  
Questionnaires 
To determine whether attitude toward food intake changed during weight loss and 
maintenance, a validated Dutch translation of the three-factor eating questionnaire 
(TFEQ) was used [16]. Changes in dietary restraint and disinhibtion scores were used 
as indicators for changes in eating behaviour and different disinhibition and restraint 
ouctomes have been associated with distinct weight and behaviour outcomes [17]. 
DNA isolation and genotyping 
Blood was collected in an EDTA tube during screening and the buffy coat was stored 
at -80°C. Genomic DNA was isolated from the buffy coat using the QIAamp mini blood 
kit (Qiagen, Amsterdam, The Netherlands). Six SNPs were selected based on GWAS 
and intervention studies, which associated them to obesity (table 1). Genotypes were 
coded 0, 1 or 2 according to the number of risk alleles for each SNP. From these 
codes a genetic predisposition score (GPS) was constructed for each individual by 
summing the risk alleles across the six SNPs, as previously done by other authors [5, 
18, 19].  
Genotyping of five SNPs was performed using commercially available TaqMan 
SNP genotyping assays from Applied Biosystems (Foster City, California, USA). The 
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procedure was performed according to the manufacturerʼs protocol and measured on 
an Applied Biosystems 7900 HT Fast Real-Time PCR system. Allelic calls were de-
termined semi-automatically using the allelic discrimination software of Applied Bio-
systems. The Pro12Ala polymorphism of the PPARγ2 gene was characterized using 
the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) 
assay. The primers used were 5ʼ-GCCAATTCAAGCCCAGTC-3ʼ and 5ʼ-
GATATGTTTGCAGACAGTGTATCAGTGAAGGAATCGCTTTCCG-3ʼ. The cycling 
conditions were 95°C for 5 min, 30 cycles of 95°C/30 s, 56°C/45 s, 68°C/45 s and 
followed by 68°C for 7 min. The restriction enzym BstU-I was used, which generated 
the following fragments: 270bp (Pro12Pro); 270, 227, 43bp (Pro12Ala) and 227, 43bp 
(Ala12Ala). 
Statistical analysis 
Data are presented as mean and their standard deviations, unless otherwise indica-
ted. A Chi-square test was used to check whether the allele frequencies were in Hardy 
Weinberg equilibrium. ANOVA repeated measures was carried out to determine 
changes over time. Mean baseline values and changes in weight during weight loss 
and follow-up periods were compared between groups with ANOVA. Corrections for 
multiple testing were performed by using Bonferroni correction. Each SNP was tested 
individually, with age, sex and baseline value for that particular dependent variable as 
covariates. Linear regressions were used to test for associations. Significance was 
defined as P<0.05. All of the statistical analyses were executed with SPSS version 
16.0 for Macintosh OS X (SPSS Inc, Chicago, IL). 
Results 
Body weight, BMI, fat mass, percentage fat mass, waist and hip circumference decre-
ased significantly during weight loss and remained significantly lower after 3-month 
follow-up compared to baseline (table 1). Dietary restraint increased and disinhibition 
and hunger decreased significantly during weight loss and remained significantly 
below baseline values during follow-up.  
 
Table 1: Subject characteristics (mean±SD) on baseline (t0), after weight loss (t2), after 3-
month (t5) and 10-month follow-up (t12). 
 t0  t2  t5  P-value# 
Body weight (kg) 92.6±12.3 83.2±10.9* 84.7±11.7* <0.001 
BMI (kg/m2) 32.0±3.1 28.7±3.0* 29.2±3.2* <0.001 
Fat mass (kg) 38.6±7.8 31.2±7.8* 30.9±8.6* <0.001 
Percentage fat mass (%) 41.6±6.6 37.4±7.4* 33.5±8.5* <0.001 
Dietary restraint  7.5±3.8 12.4±4.2* 12.0±4.2* <0.001 
Disinhibition 6.5±2.7 4.9±2.6* 5.3±2.8* <0.001 
Hunger 5.1±3.0 3.7±3.0* 3.4±2.9* <0.001 
BMI; Body Mass Index 
# Difference over time (repeated measures ANOVA)  
*Significantly different from baseline, P<0.01 
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Genetic predisposition 
All SNPs were in Hardy Weinberg equilibrium (table 2). To determine the genetic 
contribution of the selected SNPs, differences in body weight at baseline and body 
weight changes during short and long-term weight loss were compared between the 
different genotypes (table 3). Furthermore, a GPS was calculated by summing the 
risk alleles across the six SNPs. Multiple regression showed a positive association 
between GPS and body weight at baseline (table 4), with a higher GPS associated 
with a higher body weight at baseline. There was no unifying effect on body weight as 
the GPS might have suggested when the effect of the SNPs separately was assessed 
(table 3). There was a significant difference in body weight at baseline between FTO 
genotypes, with a higher body weight with the effect allele. More weight loss during 
energy restriction was associated with a high GPS (table 4). Subjects with the effect 
allele for PPARGC1A had more short-term weight loss. During long-term weight loss 
there were no significant associations with GPS. Long-term weight loss was signifi-
cantly different between MC4R genotypes, with less weight loss after 3-month follow-
up compared to baseline in subjects with the effect allele. 
Additionally, results for differences in fat mass and percentage fat mass between 
genotypes were comparable to those for body weight as reported above (data not 
shown). For dietary restraint, disinhibition and hunger scores, there were no signifi-
cant differences between genotypes. 
 
 
 
Table 2: Genotypic and allelic distributions per single nucleotide polymorphism  
Gene SNP G F(N) F(%) Allele* F(%) HWE 
FTO rs9936909 AA 25 16.9 A 38.9 0.65 
  AT 65 43.9 T 61.1  
  TT 58 39.2    
MC4R rs17782313 CC 15 10.1 C 24.1 0.19 
  CT 46 31.1 T 75.9  
  TT 87 58.8    
ADRB2 rs1042713 GG 56 37.8 G 62.3 0.92 
  GA 71 48.0 A 37.7  
  AA 21 14.2    
PPARD rs2076168 GG 16 10.9 G 28.1 0.33 
  GT 52 35.4 T 71.9  
  TT 79 53.7    
PPARGC1A rs8192678 AA 20 13.6 A 37.2 0.95 
  AG 70 47.6 G 62.8  
  GG 57 38.8    
PPARG2 rs1801282 Ala12Ala 1 0.7 Ala 10.7 0.83 
 (Pro12Ala) Pro12Ala 30 20.1 Pro 89.3  
  Pro12Pro 118 79.2    
G, genotype; F, frequency, both absolute (N) and relative (%)  
*Effect allele in bold  
P-values obtained from the χ2-test of Hardy Weinberg equilibrium (HWE). 
 
Table 3: Baseline and changes in body weight (kg) during short and long-term weight loss. 
Baseline Weight (t0) *  Short-term weight loss (t2-0)**  Long-term weight loss (t5-0) ***  Gene Effect allele Genotype 
Mean ± SE P-value Change ± SE P-value Change ± SE P-value 
FTO A AA 96.0 ± 2.4 0.017 -9.9 ± 0.8 0.333 -8.8 ± 0.6 0.411 
  AT 93.9 ± 1.3  -9.7 ± 0.4  -8.0 ± 0.4  
  TT 90.5 ± 1.3  -8.9 ± 0.4  -7.8 ± 0.4  
MC4R C CC 96.6 ± 3.1 0.353 -8.2 ± 1.0 0.422 -7.5 ± 0.9 0.049 
  CT 91.3 ± 1.6  -9.6 ± 0.5  -7.2 ± 0.4  
  TT 92.6 ± 1.2  -9.5 ± 0.4  -8.6 ± 0.3  
ADRB2 G GG 93.5 ± 1.6 0.208 -9.9 ± 0.5 0.346 -7.3 ± 0.4 0.190 
  GA 93.1 ± 1.3  -9.0 ± 0.4  -8.1 ± 0.4  
  AA 89.4 ± 2.2  -8.8 ± 0.7  -8.6 ± 0.6  
PPARD G GG 91.8 ± 2.8 0.530 -9.9 ± 0.9 0.525 -8.4 ± 0.8 0.385 
  GT 91.4 ± 1.6  -9.5 ± 0.5  -7.4 ± 0.4  
  TT 93.7 ± 1.2  -9.0 ± 0.4  -8.1 ± 0.3  
PPARGC1A A AA 92.9 ± 2.6 0.112 -10.7 ± 0.8 0.023  -9.1 ± 0.7 0.290 
  AG 94.2 ± 1.3  -9.8 ± 0.4  -7.9 ± 0.4  
  GG 91.4 ± 1.4  -8.5 ± 0.4  -7.8 ± 0.7  
PPARG2 Ala Pro12Ala 93.8 ± 2.1 0.725 -10.1 ± 0.7 0.189 -7.6 ± 0.6 0.525 
  Pro12Pro 92.3 ± 1.0  -9.2 ± 0.3  -8.0 ± 0.3  
* Adjusted for age and sex 
**Adjusted for age, sex and baseline weight 
***Adjusted for age, sex, baseline weight and weight loss (t2-0) 
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Table 4: Multiple regression between body weight and body weight changes with GPS. 
Response Parameter B ± SE β P-value 
GPS 1.14 ± 0.57 0.15 0.049 
Gender -15.38 ± 2.28 -0.52 0.000 
Baseline weight (t0)  
Age -0.03 ± 0.11 -0.02 0.821 
GPS -0.52 ± 0.18 -0.21 0.004 
Gender 2.86 ± 0.82 0.30 0.000 
Baseline weight (t0) -0.11 ± 0.03 -0.30 0.001 
Short-term weight loss (t2-0)  
Age 0.04 ± 0.04 0.07 0.317 
Response; dependent variable 
Parameter; independent variable 
B; unstandardized regression coefficient 
β; standardized regression coefficient 
Eating behaviour 
Changes in dietary restraint were inversely correlated with changes in disinhibition 
during both short and long-term weight loss (respectively R2=0.044 P=0.011 and 
R2=0.082 P<0.001). Body weight at baseline was significantly correlated with dietary 
restraint and disinhibition, but did not reach significance after adjusting for age and 
gender (table 5). In a multiple regression together with SNPs that showed a signifi-
cant effect, body weight at baseline was associated with gender and FTO. Short-term 
weight loss was associated with body weight at baseline, gender and PPARGC1A. 
Long-term weight loss was associated with the amount of weight lost during energy 
restriction, gender and the change in dietary restraint and disinhibition after 3-month 
follow-up.  
Discussion 
A high GPS was associated with a high body weight at baseline and more short-term 
weight loss. From the six selected obesity-related SNPs in this study, FTO was asso-
ciated with increased body weight at baseline. The effect allele of PPARGC1A was 
associated with short-term weight loss when assessed for each SNP separately. 
Long-term weight loss was associated with a larger increase in dietary restraint and 
larger decrease in disinhibition.  
Based on literature six SNPs were selected as being related to obesity associa-
ted-traits, and thus suggested to be candidates for associations with body weight 
changes. The correlations with GPS indicate that the SNPs have a negative effect on 
body weight, but a positive effect on short-term weight loss, with subjects with the 
most effect alleles losing more weight during energy restriction. However, when as-
sessed for each SNP separately merely FTO and body weight and PPARGC1A and 
short-term weight loss were significantly associated. For FTO rs9936909, body weight 
at baseline was higher in A-allele carriers, while there were no differences in weight 
loss consistent with previous studies [20-22]. During short-term weight loss subjects 
with the A-allele of PPARGC1A rs8192678 lost more weight, but this effect was lost  
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Table 5: Multiple regression between body weight at baseline and body weight changes with 
SNPs, dietary restraint and disinhibition. 
Response Parameter B ± SE β P-value 
Age 0.01 ± 0.10 0.00 0.959 
Gender -13.69 ± 2.17 -0.49 0.000 
FTO 3.26 ± 1.29 0.18 0.012 
Dietary restraint (t0) 0.11 ± 0.24 0.03 0.654 
Body weight (t0)  
Disinhibition (t0) -0.48 ± 0.33 -0.11 0.156 
Age 0.03 ± 0.03 0.06 0.410 
Gender 2.70 ± 0.78 0.29 0.001 
PPARGC1A -1.15 ± 0.42 -0.20 0.008 
Body weight (t0) -0.11 ± 0.03 -0.33 0.000 
Dietary restraint (t2-0) -0.06 ± 0.06 -0.07 0.346 
Short-term weight loss (t2-0)  
Disinhibition (t2-0) 0.01 ± 0.12 0.01 0.912 
Age -0.05 ± 0.03 -0.08 0.077 
Gender -1.94 ± 0.61 -0.17 0.002 
MC4R 0.57 ± 0.37 0.07 0.123 
Weight loss (t2-0) 1.02 ± 0.07 0.82 0.000 
Dietary restraint (t5-0) -0.23 ± 0.07 -0.18 0.001 
Long-term weight loss  (t5-0)  
Disinhibition (t5-0) 0.25 ± 0.11 0.12 0.024 
Response; dependent variable 
Parameter; independent variable 
B; unstandardized regression coefficient 
β; standardized regression coefficient 
 
during long-term weight loss. There were also no differences in baseline body weight 
between PPARGC1A genotypes. These results were in contrast with previous studies, 
which showed associations with body weight and not with weight changes [23, 24]. 
Long-term weight loss was significantly lower in subjects with the C-allele of MC4R 
rs17782313, while others have shown that this SNP was associated with body weight 
and not weight changes [25, 26]. In contrast to what we expected from the literature, 
there were in addition to PPARGC1A and MC4R also no significant differences in 
body weight for the ADRB2 rs1042713 and PPARD rs2076168 [27, 28]. Although not 
many studies determined the relation between SNPs and weight changes, most asso-
ciations were found with PPARG2 rs1801282 [29-33], but our results could not con-
firm this. Many explanations for the inconsistent results in the literature have already 
been proposed, like low sample size, limitations of study populations and different 
study designs. However, a probably more important factor is the largely unknown 
gene-environment interactions that can mask the effect of a genetic variant, as de-
scribed by Andreasen et al. [34]. Especially during a period of conscious weight loss, 
behavioural changes might dominate genetic effects. Furthermore, comparing studies 
using GPS is difficult, because a calculated GPS is not a constant variable and is 
different in each study depending on the different SNPs selected. 
Dietary restraint and disinhibition have emerged from the literature as important 
indicators for eating behaviour and different disinhibition and restraint outcomes have 
been associated with distinct weight and behaviour outcomes [17]. Here, changes in 
dietary restraint and disinhibition were inversely correlated with each other consistent 
with previous studies [35-38]. Both changes in dietary restraint and disinhibition were 
correlated with long-term weight loss, emphasizing the importance of both factors 
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during periods of weight maintenance. These results confirm findings of previous 
studies that already have shown that the increase in dietary restraint was associated 
with more success in weight maintenance [37, 39, 40]. There was no effect of the 
SNPs on dietary restraint and disinhibition or changes in these factors, so changes in 
eating behavior independently predict success in long-term weight loss.  
From these results we cannot exclude whether there were gene-environment in-
teractions masking effects of a genetic variant. In turn, dietary restraint and disinhibiti-
on not fully cover behavioural factors, though widely used to characterize eating be-
havior. In addition, six SNPs as measured in 150 subjects are low compared to other 
genetic studies. However, this is a consequence of the design of our study, since 
accurate assessment of short and long-term weight loss were limiting factors. Since 
these measurements are part of a larger intervention study, the selection of the SNPs 
comprised those previously associated with obesity-related traits in general and not 
specifically personality traits.  
In conclusion, long-term weight loss is mainly determined by changes in eating 
behaviour. 
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Abstract 
Adipocyte size is a major modulator of endocrine functioning of adipose tissue and 
methods allowing accurate determination of adipocyte size are important to study 
energy metabolism. The aim of this study was to assess the relative shrinkage of 
adipocytes before and after weight loss by comparing adipose tissue from the same 
subjects embedded in paraffin and plastic. 18 healthy subjects (5 males, 13 females) 
aged 20-50 y with a BMI of 28-38 kg/m2 followed a very low energy diet for 8 weeks. 
Adipose tissue biopsies were taken prior to and after weight loss and were processed 
for paraffin and plastic sections. Parameters of adipocyte size were determined with 
computer image analysis. Mean adipocyte size was smaller in paraffin compared to 
plastic embedded tissue both before (66±4 vs 103±5 µm, P<0.001) as after weight 
loss (62±4 vs 91±5 µm, P<0.001). Relative shrinkage of adipocytes in paraffin em-
bedded tissue in proportion to plastic embedded tissue was not significantly different 
before and after weight loss (73 and 69%, respectively). Shrinkage due to the type of 
embedding of the adipose tissue can be ignored when comparing before and after 
weight loss. Plastic embedding of adipose tissue provides more accurate and sensiti-
ve results. 
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Introduction 
A major function of adipose tissue is storage and release of energy. Additionally, adi-
pose tissue functions as an endocrine organ regulating energy expenditure, food 
intake and glucose metabolism. The extent of regulation, through secretion of hormo-
nes by the adipocytes, depends on the adipocyte size. Accordingly, adipocyte hyper-
trophy, a characteristic of obesity, leads to functional changes like increased inflam-
mation and is hypothesized to thereby cause insulin resistance (1, 2). Therefore, it is 
important to determine adipocyte size and that methods used are accurate.   
Many methods are described for determining adipocyte size, each with its advan-
tages and disadvantages (3). Measurements of triglyceride content per DNA content 
of adipose tissue as an estimation for adipocyte size is a relatively easy method, alt-
hough prone to underestimation since DNA content also reflects other cell types. 
Another technique is fixation in osmium tetroxide combined with direct electronically 
counting of adipocyte number. Dividing lipid weight of a comparable sample by the 
electronically determined cell number is used to calculate mean adipocyte size. Dis-
advantages of this technique are the toxicity of osmium tetroxide and the overestima-
tion of cell size due to the cell swelling caused by osmium. These methods also do not 
provide information on adipocyte size distribution. In contrast, collagenase treatment 
does separate adipocytes from stromal-vascular cells and followed by microscopic 
determination of cell size, adipocyte size distribution can be determined. One major 
disadvantage of this method is that large adipocytes break by the treatment, leading 
to underestimation of cell size. Measurements should be performed immediately after 
the collagenase treatment, because the cells cannot be stored without affecting cell 
morphology. On the contrary, fixed histological sections can be stored until analysis 
and cell size distribution is maintained.   
Beside the techniques used to process the tissue, the method of measuring cell 
size is also important. Manually measuring adipocyte size is a tedious and time-
consuming process. In contrast, computerized determination of adipocyte size allows 
measuring a large number of adipocytes in a rapid and reliable manner. Introducing a 
minimum and maximum value, below and above which cells are excluded from the 
analysis, prevents inclusion of artifacts. In addition, such cut off points help to exclude 
other cell types, like pre-adipocytes, from the analysis. 
Fixation, embedding and cutting cause shrinkage and compression of the tissue. 
Paraffin is commonly used as embedding, whereas plastic embedding allows cutting 
thinner sections and gives better support to the cellular components, thereby impro-
ving morphology and minimizing cell shrinking. Shrinkage in paraffin-embedded tissue 
from various organs was reported to be 10-50%, while shrinkage in plastic-embedded 
tissues was reported to range from 3-13% (4-6). Especially adipose tissue is suscep-
tible to cell shrinking because of the large lipid droplet comprising the largest part of 
adipocytes. This high lipid content in adipose tissue also results in a strong anti-freeze 
feature, and consequently we were unsuccessful in preparing cryostat sections from 
our human adipose tissue samples. In the present study, paraffin and plastic (Tech-
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novit 8100) embedded human adipose tissue derived prior to and after weight loss 
were compared to assess relative shrinkage of adipocytes.  
Material and methods 
Subjects 
Subjects were 4 males and 9 females aged 20-50 y with a BMI of 28-38 kg/m2, who 
participated in a weight loss study. The weight loss diet consisted of 8 weeks very low 
energy diet providing 2.1 MJ/day (Modifast; Nutrition et Santé Benelux, Breda, The 
Netherlands). Biopsies were taken and body weight was determined at rest and follo-
wing an overnight fast, both before and after weight loss. The study was conducted 
according to the guidelines laid down in the Declaration of Helsinki and procedures 
involving human subjects were approved by the Central Committee on Human Re-
search and by the Medical Ethical Committee of the Maastricht University. Written 
informed consent was obtained from all subjects. 
Biopsy 
An abdominal subcutaneous adipose tissue sample was obtained by needle aspirati-
on under local anaesthesia (2% lidocaine). Samples were rinsed in sterile cold saline 
and stored in 4% formaldehyde. Part of the sample was dehydrated and embedded in 
paraffin, the other part of the sample was dehydrated with 100% acetone and embed-
ded in Technovit 8100 (Heraeus Kulzer GmbH, Germany). Sections of 5µm were cut 
and stained with hematoxylin and eosin. 
Image analysis 
The sections were viewed with a Leica DMRE microscope, objective 20X, Leica ca-
mera DC500 and images were obtained with Leica Image Manager (IM50), version 
1.20 (Leica Microsystems AG, Switzerland). An image analysis computer programme 
(Leica QWin V3) was used to determine diameter (µm) and area (µm2) of the adipocy-
tes based on the method of Chen and Farese (3). Results were directly loaded into a 
spreadsheet program (Excel; Microsoft Inc.) for analysis. Diameters <40µm were 
assumed to represent artifacts or types of cells other than adipocytes and were exclu-
ded from analysis. Further analyses were done on results per subject. Adipocyte 
volume was calculated with the Goldrick formula (7). Relative shrinkage of paraffin-
embedded tissue in relation to plastic-embedded tissue was estimated by: 1- (volume-
paraffin/ volumeplastic). A minimum of 250 cells was measured per subject per time point.  
Statistical analysis 
Data are presented as mean with the standard deviations, unless otherwise indicated. 
A paired t-test (two-tailed distribution) was carried out to determine possible differen-
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ces between mean values. All frequency distributions were normally distributed. Signi-
ficance was defined as P<0.05. All of the statistical analyses were executed with 
SPSS version 16.0 for Macintosh OS X (SPSS Inc, Chicago, IL). 
Results 
After weight loss mean adipocyte diameter and area were decreased in both paraffin 
and plastic embedded tissues (figure 1). This is visualized by a shift in the frequency 
distribution of the adipocyte diameter for both paraffin and plastic embedded tissue 
(figure 2). Comparing paraffin and plastic, mean adipocyte diameter (66±4 vs 103±5 
µm, P<0.001 before weight loss and 62±4 vs 91±5 µm, P<0.001 after weight loss), 
area (3621±434 vs 8746±802 µm2, P<0.001 before weight loss and 3160±401 vs 
6883±832 µm2, P<0.001 after weight loss) and volume (174990±31505 vs 
662751±90039 µm3, P<0.001 before weight loss and 142625±27657 vs 
466669±87273 µm3, P<0.001 after weight loss) were smaller in paraffin embedded 
tissue both before and after weight loss. Hence, adipocytes shrink due to weight loss 
as well as embedding, with paraffin causing more shrinkage. However, the percenta-
ge decrease in diameter and area due to weight loss was not significantly different in 
plastic compared to paraffin embedded tissue. In addition, relative shrinkage of adipo-
cytes in paraffin embedded tissue in proportion to plastic embedded tissue was 0.73 ± 
0.05 before weight loss and 0.69 ± 0.05 after weight loss (range 0.58 to 0.82) (figure 
3). This difference was not statistically significant. 
 
 
 
Figure 1. Mean (± SD) adipocyte diameter (µm) both pre (solid) and post (dashed) weight loss 
in paraffin (black) and plastic (grey) embedded tissue. Significant differences; * P<0.01, ** 
P<0.001 (paired t-test). 
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Figure 2. Frequency distribution of adipocyte diameter (µm) both pre (solid) and post (dashed) 
weight loss in paraffin (black) and plastic (grey) embedded tissue. 
 
 
Figure 3. Relative shrinkage of adipose tissue in paraffin embedded tissue in proportion to 
plastic embedded tissue estimated by: 1- (volumeparaffin / volumeplastic). 
 
In plastic embedded tissue adipocytes were more round after weight loss (2.00 ± 
0.10 vs 2.12 ± 0.13, P<0.05), but there was no difference in roundness in paraffin 
embedded tissue before and after weight loss. However, before weight loss adipocy-
tes had a higher roundness in paraffin compared to plastic embedded tissue (1.82 ± 
0.17 vs 2.12 ± 0.13, P<0.01). Possibly due to cell shrinking the cell membrane loo-
sens and the extracellular space increases, which results in rounder adipocytes. In 
plastic the original cell structure is more preserved and therefore shrinking due to 
weight loss might cause the change in roundness of adipocytes in plastic and not in 
paraffin embedded tissue. The difference in roundness between paraffin and plastic 
before weight loss is probably caused by cell shrinking due to paraffin embedding. 
After weight loss this difference in roundness did not reached significance (P=0.09).  
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Figure 4. Microscopic picture of plastic (A-B) and paraffin (C-D) embedded adipose tissue 
before (A-C) and after (B-D) weight loss in one subject with a 20x magnification (scale in mm). 
 
Differences in overall morphology in plastic and paraffin embedded tissue can be 
seen in the microscopic pictures shown in figure 4. 
Discussion 
Adipocytes in paraffin embedded adipose tissue had a lower mean cell diameter and 
area before and after weight loss. Mean relative shrinkage of adipocytes in paraffin 
embedded tissue in proportion to plastic embedded tissue was 73 and 69% before 
and after weight loss, respectively.  
Already in 1974 Fletcher compared plastic embedded avian tissues with the more 
conventional paraffin method and found that cell shrinkage was lower and fewer sec-
tioning artifacts were present in plastic embedded tissue (8). Recently, advantages of 
plastic embedding over paraffin in human bone tissue have been reported (9, 10). 
One disadvantage is that sectioning of plastic embedded tissue is more time consu-
ming compared to paraffin. However, the advantages outweigh the disadvantages, 
since artifacts and cell shrinking do influence results that are based on morphological 
features.  
The majority of studies using paraffin or plastic embedding to evaluate morpholo-
gical characteristics of tissues do not include measurements of shrinkage. However, 
interpretation of quantitative parameters or density and size estimations may be very 
difficult without knowledge of the degree of shrinkage. Here, we defined relative shrin-
kage of paraffin embedded adipose tissue in proportion to plastic embedded adipose 
tissue, since plastic is suggested to virtually remove shrinkage (6). Paraffin embed-
ding caused a relative shrinkage of about 70% in proportion to plastic embedding. 
This is high compared to findings from other studies, which reported shrinkage from 
10-50% in different organs (4-6). The use of adipose tissue in this study probably 
caused this high relative shrinkage, since adipose tissue is susceptible to cell shrin-
king because of the large lipid droplet comprising the largest part of adipocytes. Alt-
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hough the high relative shrinkage, paraffin embedding produced consistent results in 
the different tissues. Relative shrinkage was not significantly different in adipose tis-
sue before and after weight loss. Therefore, the shrinkage of adipose tissue due to 
embedding in this study can be ignored.  
High cell shrinking due to paraffin embedding might have consequences for inter-
pretation of results. The degree of cell shrinkage might be important for defining cut 
off points, in order to exclude cells other than adipocytes. Beside some studies that do 
not even take into account such cut off points (2, 11-15), the values that are used as 
cut off point vary greatly (16, 17). In this study a diameter of 40 µm was used as a cut 
off point for both paraffin and plastic embedded tissues. Since several methods of 
processing result in different degrees of cell shrinking, therefore the use of the same 
cut off points for different methods might be questioned. Another consequence of 
higher cell shrinking in paraffin embedded tissue is a lower sensitivity to detect signifi-
cant differences in cell size measurements.  
One explanation for the continuous use of paraffin embedded tissue is immuno-
histochemical staining, since the effectiveness largely depends on the type of fixation, 
preparation and embedding. The advantage of paraffin embedding for immunohisto-
chemical staining is the lack of chemical interaction with the tissue. Recently, immu-
nohistochemical staining of bone tissue embedded with Technovit 9100 New showed 
a stronger immunostaining for several markers and a better preservation of trabecular 
bone morphology compared to paraffin embedding (9, 10). Because of the continuous 
use of paraffin, most protocols for immunohistochemical staining are optimized for this 
type of embedding. However, when protocols would be optimized for plastic embed-
ded tissues, the morphological advantages of this technique could also be exploited 
when immunohistological staining is required. One disadvantage is the higher costs 
associated with plastic embedding. 
A limitation of our study is the small sample size of our population with both male 
and females and a relatively large variation in age and BMI. Age, BMI and sex could 
have an effect on adipocyte size. However, by comparing both techniques by defining 
relative shrinkage of paraffin-embedded tissue in relation to plastic-embedded tissue 
within the same subjects before and after weight loss, we believe that a possible ef-
fect of age, BMI and sex on adipocyte size would not influence our conclusion. 
In conclusion, shrinkage of adipose tissue due to the type of embedding in this 
study can be ignored, since relative shrinkage was not significantly different in adipo-
se tissue before and after weight loss. However, paraffin embedded tissue resulted in 
higher cell shrinkage and has the disadvantage of poorer morphology. Therefore, 
plastic embedding is more accurate and susceptible to detect differences in adipocyte 
size caused by weight loss.  
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Abstract 
Metabolic processes in adipose tissue are dysregulated in obese subjects and, in 
response to weight loss, either normalize or change in favor of weight regain. To de-
termine changes in adipocyte glucose and fatty acid metabolism in relation to changes 
in adipocyte size during weight loss and maintenance. Twenty-eight healthy subjects 
(12 males), age 20-50y, and BMI 28-35kg/m2, followed a very low energy diet for 2 
months, followed by a 10-month period of weight maintenance. Body weight, body 
composition (deuterium dilution and BodPod), protein levels (Western blot) and adipo-
cyte size were assessed prior to and after weight loss and after the 10-month follow-
up. A 10% weight loss resulted in a 16% decrease in adipocyte size. A marker for 
glycolysis decreased (AldoC) during weight loss in association with adipocyte shrin-
king, and remained decreased during follow-up in association with weight maintenan-
ce. A marker for fatty acid transport increased (FABP4) during weight loss and remai-
ned increased during follow-up. Markers for mitochondrial beta-oxidation (HADHsc) 
and lipolysis (ATGL) were only increased after the 10-month follow-up. During weight 
loss HADHsc and ATGL were coordinately regulated, which became weaker during 
follow-up due to adipocyte size-related changes in HADHsc expression. AldoC was 
the major denominator of adipocyte size and body weight, whereas changes in ATGL 
during weight loss contributed to body weight during follow-up. Upregulation of ATGL 
and HADHsc occured in the absence of a negative energy balance and was triggered 
by adipocyte shrinkage or indicated preadipocyte differentiation. Markers for adipocyte 
glucose and fatty acid metabolism are changed in response to weight loss in line with 
normalization from a dysregulated obese status to an improved metabolic status. 
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Introduction 
Adipose tissue is a major energy-storing tissue and to fulfill this role adipocytes need 
to respond rapidly to alterations in nutrient deprivation and excess by metabolic regu-
lation. Many studies found evidence for involvement of metabolic processes in the 
development of obesity, like a reduced fat oxidation in obese humans (1-3). But also 
inside the adipocyte these metabolic processes are linked to obesity. Walewski et al. 
showed that an increased uptake and reduced metabolism of long chain fatty acids 
contribute to the accumulation of these long chain fatty acids in obese adipocytes (4). 
Furthermore, an impaired hormone-sensitive lipase protein expression in adipose 
tissue of obese subjects suggests a decreased lipolysis in obesity (5). Studies on 
weight loss indicate that caloric restriction results in changes in the expression of 
genes involved in lipid, carbohydrate and energy metabolism in adipose tissue (6) and 
proteins regulating adipose tissue growth (7). Also the endocannabinoid system is 
dysregulated in adipose tissue in the obese state, but is normalized after weight loss 
(8). 
However, successfully maintaining weight loss, defined as “keeping off an intenti-
onal loss of at least 10% body weight for at least one year” (9), is difficult and is only 
achieved in around 20% of the cases (10). The biological response to weight loss is 
causing the susceptibility to weight regain as reviewed by MacLean et al. (11). This 
response is a network of adaptations with an energy gap promoting regain and phy-
siological changes resulting in resistance for further weight loss as was summarized 
by Mariman (12). Few studies assessed the effect of weight loss maintenance on 
gene expression in subcutaneous adipose tissue (13-15). Genes involved in proces-
ses like fatty acid metabolism, citric acid cycle, oxidative phosphorylation and apopto-
sis were differentially expressed during weight loss and maintenance thereafter (13-
15). Mutch et al. showed that the regulation of these genes by weight loss was diffe-
rent between weight maintainers and weight regainers, which was suggested to pre-
dict successful short-term weight maintenance (15).  
Our objective was to determined changes in markers for adipocyte glucose and 
fatty acid metabolism during weight loss and maintenance by measuring protein levels 
before and after an 8-week very low energy diet and after a 10-month follow-up in 
order to find out whether these changes are associated with adipocyte size and are in 
line with weight regain or maintenance.  
Methods 
Ethics statement 
All procedures were carried out with the adequate understanding and written informed 
consent of the subjects. The study was conducted according to the guidelines laid 
down in the Declaration of Helsinki and was approved by the Central Committee on 
Human Research and by the Medical Ethical Committee of the University of Maa-
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stricht. The study was registered in ClinicalTrials.gov (registration number: 
NCT01015508). The protocol described here in this study deviates from the trial pro-
tocol approved by the Medical Ethical Committee of the University of Maastricht  (adi-
pocyte size is determined differently and protein levels measurements are not expli-
citly described) as it comprises only a part of the approved trial protocol.  
Subjects 
Thirty-one healthy subjects (13 males, 18 pre-menopausal females) aged 20-50 y with 
a BMI of 28-35 kg/m2 were recruited by advertisements in local newspapers and on 
notice boards at the university. Subjects underwent a screening and all were in good 
health, nonsmokers, not using medication (except for oral contraception) and modera-
te alcohol users. None of the subjects gained or lost more than 5 kg in three months 
prior to the study. The weight loss diet consisted of 8 weeks very low energy diet 
providing 2.1 MJ/day (Modifast; Nutrition et Santé Benelux, Breda, The Netherlands). 
This diet was a protein-enriched formula diet that provided 50g carbohydrates, 52g 
protein, 7g fat and a micronutrient content, which meets the Dutch recommended daily 
allowance. Vegetables were allowed in addition to the diet. The weight loss period 
was followed by a follow-up period of 10 months, in which subjects were instructed to 
maintain their newly achieved body weight without a prescribed diet. Subjects did 
receive advise on how to monitor and limit their food intake concerning both quantity 
as well as quality at all test days after weight loss.  Measurements were done at rest 
and following an overnight fast at three time points; before weight loss (t0), after 
weight loss (t2) and after 10 months follow-up (t12).  
Anthropometry 
Height was measured at screening to the nearest 0.1cm with the use of a wall-
mounted stadiometer (model 220; Seca, Hamburg, Germany). Body weight was mea-
sured with subjects in underwear after an overnight fast using a calibrated scale of the 
BodPod®. Body mass index (BMI) was calculated by dividing body weight by height 
squared (kg/m2). Fat distribution was assessed by measuring the waist circumference 
at the site of the smallest circumference between the rib cage and the ileac crest, with 
the subjects in standing position. Hip circumference was measured at the site of the 
largest circumference between waist and thighs.  
Body composition was calculated from body volume of the BodPod® (Life measu-
rement, Concord, CA, USA) (16) and total body water (TBW) (17) of the deuterium 
dilution technique, using Siriʼs three-compartment model (18). The dilution of the deu-
terium isotope (2H2O) is a measure for total body water. Subjects wore tightly fitting 
bathing suits and a swim cap during the volume-measurements in the BodPod, and 
had not engaged in exercise at least 1 hour prior to the test.  
Blood parameters 
Fasted blood samples were taken and collected in EDTA containing tubes to prevent 
clotting. Plasma was obtained by centrifugation and stored at -80°C until further ana-
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lysis. Leptin, insulin and adiponectin concentrations were measured with the use of 
the human RIA kit (respectively, Millipore, St Charles, MO, USA, Kabi-Pharmacia, 
Uppsala, Sweden and Millipore, St Charles, MO, USA).  
Western blot analysis 
Five proteins involved in glucose and fatty acid metabolisms were selected and mea-
sured in adipose tissue by Western blotting. Fructose-bisphosphate aldolase C (Al-
doC) is an enzyme of the glycolysis and involved in the formation of triglycerides. 
Fatty acid binding protein 4 (FABP4) is an indicator for fatty acid handling inside the 
adipocyte by facilitating the intracellular transport of fatty acids. Adipose triglyceride 
lipase (ATGL) and short chain 3-hydroxyacyl-CoA dehydrogenase (HADHsc) are rate-
limiting enzymes of respectively lipolysis and mitochondrial beta-oxidation. Finally 
catalase represents peroxisomal beta-oxidation because it is responsible for conver-
ting the harmful product of this reaction, hydrogen peroxide.  
Abdominal subcutaneous adipose tissue biopsies (approximately 1.5g) were ob-
tained by needle liposuction under local anaesthesia (2% lidocaine, Fresenius Kabi 
BV, The Netherlands) after an overnight fast, before and after the diet. Samples were 
rinsed in sterile cold saline, frozen in liquid nitrogen and stored at -80°C until protein 
isolation. 
Frozen adipose tissue was grinded in a mortar and the powder was dissolved in 
200µl of 8M urea, 2% CHAPS, 65mM DTT per 100mg powder. The homogenate was 
vortexed for 5 min and centrifuged for 30 min at 14000rpm and 10°C. The supernatant 
containing the adipose tissue proteome was carefully collected and aliquots were 
stored at -80°C. Protein concentrations were determined by a Biorad Bradfort-based 
protein assay (19). 
Samples with equal amount of protein were run on a 12% SDS polyacrylamide gel 
(180 V, Criterion Cell; Biorad, Hercules, CA) and then transferred (90 min, 100 V, 
Criterion blotter; Biorad) to 0.45-mm nitrocellulose membranes. After Ponceau S stai-
ning and destaining, membranes were blocked in 5% bovine serum albumin (BSA) in 
Tris-buffered saline containing 0.1% Tween 20 (TBST) for AldoC and 5% nonfat dry 
milk powder in TBST for catalase, FABP4, ATGL and HADHsc for 1 h. Thereafter, the 
blots were incubated with the primary antibodies against AldoC (1:250 dilution, Santa 
Cruz sc-12066), catalase (1:500 dilution, Santa Cruz sc69762), FABP4 (1:1000 diluti-
on, Cayman 10004944), ATGL (1:250 dilution, Cell Signaling 2138) and HADHsc 
(1:500 dilution, Santa Cruz sc-74650) in 5% BSA-TBST (AldoC), 0.5% nonfat dry milk 
powder TBST (ATGL) or 5% nonfat dry milk powder TBST (catalase, FABP4, HADH-
sc) overnight at 4°C on a shaker. Thereafter, the blots were washed three times for 10 
min in TBST, and then incubated with 1:10000 dilution of the horseradish peroxidase-
conjugated secondary antibody (DAKO) in 5% BSA-TBST, 0.5% nonfat dry milk pow-
der TBST or 5% nonfat dry milk powder TBST for 1 h. The blots were washed three 
times for 10 min in TBST. A CCD camera (XRS-system, Biorad) was used to detect 
immunoreactive bands using chemiluminescent substrate (SuperSignal CL; Pierce). 
The quantification was performed with the program Quantity One version 4.6.5 (Bio-
rad). Blots were normalized to β-actin (1:1000 dilution, Santa Cruz sc-47778) to cor-
rect for differences in protein loading.  
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Adipocyte size 
Part of the biopsies was rinsed in sterile cold saline and stored in 4% paraformalde-
hyde. Tissues were dehydrated and embedded in paraffin. Section of 5µm were cut 
and stained with hematoxylin and eosin. The sections were viewed at 20x magnificati-
on, and images were obtained with Leica Image Manager (IM50), version 1.20 (Leica 
Microsystems AG, Switzerland). An image analysis computer programme (Leica 
QWin V3) was used to determine adipocyte area (µm2) and diameter (µm) based on 
the method of Chen and Farese (20). Results were directly loaded into a spreadsheet 
program (Excel; Microsoft Inc.) for analysis. Diameters <40µm were assumed to re-
present artifacts or types of cells other than adipocytes and were excluded from ana-
lysis. Volume was calculated with the Goldrick formula (21). A minimum of 250 cells 
was measured per subject per time point.  
Statistical analysis 
Data are presented as mean and their standard errors, unless otherwise indicated. A 
paired t-test (two-tailed distribution) was carried out to determine possible differences 
between mean values. Spearman Rhoʼs correlation coefficients were calculated for 
associations between parameters. ANOVA repeated measures was carried out to 
determine possible differences over time with gender as covariate. Significance was 
defined as P<0.05. The power calculation was based on a weight loss study, in which 
a significant 3-fold increase in ATGL and a 2-fold increase in HADHsc levels was 
measured with Western blotting during weight loss in 8 obese subjects (submitted, 
Bouwman et al.). With an α of 0.05, β of 0.10, mean change of respectively 0.177 and 
0.285, and standard deviations of respectively 0.180 and 0.223 for ATGL and HADH-
sc, and taking into account an expected success-rate of 20% during weight mainte-
nance and a dropout rate of 15%, at least 29 subjects needed to be included at the 
start of the study. All of the statistical analyses were executed with SPSS version 16.0 
for Macintosh OS X (SPSS Inc, Chicago, IL). 
Results 
Subject characteristics 
Three subjects dropped out during follow-up, thus 28 subjects (12 males, 16 females) 
aged 39 ± 2 y completed the study and from those biopsies were taken at the three 
time points. Blood samples were available from 13 subjects (7 males and 6 females), 
with no significant differences in weight loss and weight maintenance thereafter bet-
ween these 13 subjects and the other 15 subjects.  
Subject characteristics at t0, t2 and t12 are shown in table 1. Average weight loss 
was 10 ± 0.6 % (range 4-17%) and 82% of this lost weight was fat mass. This was 
accompanied by a decrease in adipocyte volume of 16 ± 0.1 %. Weight loss was also 
accompanied by a decrease in leptin and a trend towards a decrease in insulin levels 
(P=0.106). During follow-up BMI significantly increased, although there was a large 
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Table 1. Anthropometric parameters (mean±SEM) at t0, t2 and t12 (n=28). 
 t0 t2 t12 P-value* 
Body weight (kg) 96.9 ± 2.7 87.2 ± 2.3 91.7 ± 2.6 <0.001 
BMI (kg/m2) 31.8 ± 0.5 28.6 ± 0.5 30.1 ± 0.6 <0.001 
Waist circumference (cm) 97.8 ± 2.1 89.2 ± 1.6 92.6 ± 1.8 <0.001 
Hip circumference (cm) 113.6 ± 1.6 107.5 ± 1.5 109.2 ± 1.6 <0.001 
Fat mass (kg) 38.9 ± 1.4 30.9 ± 1.4 34.4 ± 1.5 <0.001 
Percentage fat mass (%) 40.2 ± 1.0 35.5 ± 1.3 37.4 ± 1.2 <0.001 
Adipocyte diameter (µm) 66.9 ± 0.6 63.2 ± 1.0 65.2 ± 1.0 0.005 
Adipocyte volume (*105µm3) 1.8 ± 0.0 1.5 ± 0.1 1.7 ± 0.1 0.013 
Leptin# (µg/L) 20.3 ± 2.9 13.1 ± 3.4 17.8 ± 4.6 0.005 
Insulin# (mU/L) 18.4 ± 2.2 14.7 ± 2.1 19.6 ± 5.4 NS 
Adiponectin# (µg/L) 17.0 ± 2.1 18.0 ± 2.6 17.0 ± 3.5 NS 
* ANOVA repeated measures 
# n=13 
BMI, Body Mass Index 
 
variation. As expected, only 18% of the subjects were successful in maintaining their 
reduced weight or even continued to lose weight during the 10-month follow-up (10). 
Average adipocyte volume did not change significantly during follow-up, but the chan-
ges in adipocyte volume were positively correlated with changes in body weight bet-
ween t0 and t12 (P=0.007, r=0.519). 
Proteins 
Protein levels are depicted in figure 1. Correlation analysis between the changes in 
protein levels and changes in adiposity parameters are depicted in table 2. No signifi-
cant correlations were found with changes in adiponectin levels. Fructose-
bisphosphate aldolase C (AldoC) decreased during weight loss and remained decrea-
sed during follow-up (figure 1A). Changes in AldoC were positively correlated with 
changes in body weight and adipocyte size.  
Fatty acid binding protein 4 (FABP4) increased during weight loss and remained in-
creased during follow-up, with a trend towards an additional increase between t2 and 
t12 (P=0.058) (figure 1B). During follow-up changes in FABP4 were positively correla-
ted with changes in body weight, whereas changes in FABP4 during weight loss were 
inversely correlated with changes in body weight during follow-up. Short chain 3-
hydroxyacyl-CoA dehydrogenase (HADHsc) increased during follow-up (figure 1C). 
Changes in adipocyte size during weight loss were inversely correlated with changes 
in HADHsc during follow-up. Adipose triglyceride lipase (ATGL) also increased during 
follow-up (figure 1D). Changes in ATGL during weight loss were positively correlated 
with changes in body weight during follow-up. Catalase on average did not signifi-
cantly change over time (figure 1E). However, there was a trend towards an inverse 
correlation between changes in catalase and changes in body weight and adipocyte 
size during follow-up. In addition there was a trend towards a positive correlation bet-
ween changes in catalase during weight loss and changes in adipocyte size during 
follow-up. 
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Figure 1. Protein levels measured with Western blots over time. AldoC (A), FABP4 (B), HADHsc 
(C), ATGL (D) and Catalase (E) levels (arbitrary units) at t0 (black), t2 (grey) and t12 (white) 
(mean±SEM). *P<0.05 with repeated measures ANOVA. 
 
The correlations between the changes in protein levels are listed in table 3. 
Changes in AldoC, HADHsc and catalase during weight loss were inversely correlated 
with changes during follow-up. Changes in FABP4 are positively correlated with chan-
ges in both HADHsc and ATGL. In turn, changes in ATGL and HADHsc during weight 
loss are positively correlated, whereas changes in ATGL during weight loss are inver-
sely correlated with changes in HADHsc during follow-up. Changes in catalase are 
inversely correlated with changes in HADHsc, but positively correlated with changes 
in AldoC. Changes in AldoC and changes in HADHsc between t0 and t12 were inver-
sely correlated.  
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Discussion 
Measuring proteins involved in glucose and fatty acid metabolism before and after an 
8-week very low energy diet and after a 10-month follow-up revealed a decreased 
marker for glycolysis (decreased AldoC) and increased marker for fatty acid transport 
(increased FABP4) after weight loss sustained during weight maintenance. There was 
a delayed response in fatty acid metabolism with increased markers for lipolysis (in-
creased ATGL) and mitochondrial beta-oxidation (increased HADHsc) during follow-
up.  
The changes in catalase, HADHsc and AldoC during weight loss were inversely 
correlated with the changes of these proteins during follow-up. These correlations 
remained significant in a multiple regression analysis taking into account body weight 
loss (data not shown). The transition from weight loss to follow-up seems to have a 
major impact on markers for beta-oxidation and glycolysis. This is probably due to 
switching from a negative energy balance after the 8-week very low energy diet to a 
normal diet during the follow-up. Results here are in line with previous research that 
did take into account a 3-week maintenance interval to remove possible immediate 
effects of a negative energy balance (22).  
The increase in FABP4 during weight loss, which was sustained during the 10-
month follow-up, indicates an increased marker for intracellular trafficking of fatty 
acids. Together with the decrease in adipocyte size this suggests that there would be 
an increased lipolysis. However, against our expectations we found no significant 
increase of ATGL during weight loss. This could be due to a sufficient lipolytic capaci-
ty or that a decrease in lipid content is the result of another mechanism like autopha-
gia (23, 24). Despite the lack of an increase in ATGL during weight loss, correlations 
between changes in protein levels demonstrate a coordinated regulation of ATGL, 
HADHsc and CAT indicating cross-talk between markers for lipolysis and mitochon-
drial and peroxisomal β-oxidation. There was an inverse correlation between changes 
in ATGL during weight loss and changes in HADHsc during the follow up (figure 2). 
This correlation remained significant in a multiple regression analysis taking into ac-
count body weight loss (data not shown), but may be simply the consequence of other 
correlations. Nevertheless, the coordination between those processes of FA-handling 
becomes weaker during follow-up. According to the correlation analysis, the weake-
ning of the coordination between FA-handling processes may be related to changes in 
adipocyte size during weight loss, which may influence the HADHsc expression during 
follow-up. Shrinking of adipocytes during weight loss has been reported to generate 
cellular stress (22, 25, 26) and the more they shrink, the higher will be the resistance 
against increasing mitochondrial beta-oxidation via HADHsc during follow-up. 
During development of obesity, the capacity of lipolysis and beta-oxidation decre-
ase (1-3). In this respect, the increase of both ATGL and HADHsc suggest that weight 
loss induces an improved homeostasis. The fact that this process only starts after the 
end of the weight loss period indicates that it is inhibited by a negative energy balan-
ce. The increase in ATGL and HADHsc may be triggered by the shrinking of the adi-
pocytes, but may also be the result of differentiation of preadipocytes, which in the rat 
has been observed after weight loss (5, 11). Newly differentiated adipocytes are me-
tabolically active, which will contribute to an improved physiological status. 
 
Table 2. Spearman Rhoʼs correlation coefficients of changes in protein levels with changes in adiposity parameters. 
  Aldolase C FABP4 HADHsc ATGL Catalase 
Parameter  t2-0 t12-2 t12-0 t2-0 t12-2 t12-0 t2-0 t12-2 t12-0 t2-0 t12-2 t12-0 t2-0 t12-2 t12-0 
Body weight  t2-0                
(kg) t12-2  0.483b  -0.405a 0.414a     0.561b  0.532b   -0.399a 
 t12-0   0.450b  0.635c           
Adipocyte size  t2-0 0.562b       -0.462b        
(*105µm3) t12-2  0.372a           0.398a -0.388a  
 t12-0   0.411a             
Leptin#  t2-0   -0.667b             
(µg/L) t12-2                
 t12-0                
Insulin#  t2-0   -0.700b 0.576a            
(mU/L) t12-2    -0.886b 0.829b           
 t12-0                
# n=13 
a P<0.1 
b P<0.05 
c P<0.01 
BMI, Body Mass Index 
 
 
  
Table 3. Spearman Rhoʼs correlation coefficients of changes in protein levels with each other. 
 Aldolase C FABP4 HADHsc ATGL Catalase 
  t2-0 t12-2 t12-0 t2-0 t12-2 t12-0 t2-0 t12-2 t12-0 t2-0 t12-2 t12-0 t2-0 t12-2 t12-0 
Aldolase C t2-0                
 t12-2 -0.488b               
 t12-0 0.564c               
FABP4 t2-0                
 t12-2                
 t12-0    0.396a 0.739c           
HADHsc t2-0                
 t12-2       -0.542c         
 t12-0   -0.461b  0.481b 0.458b  0.583c        
ATGL t2-0  0.545a     0.618b -0.618b        
 t12-2     0.500a 0.643b          
 t12-0      0.516a    0.689c 0.889c     
Catalase t2-0       -0.740c         
 t12-2           -0.564a  -0.697c   
 t12-0   0.500b    -0.482b  -0.552b    0.571c   
a P<0.1 
b P<0.05 
c P<0.01 
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Changes in parameters of adiposity were correlated with changes in AldoC. This 
indicates that successful weight maintainers sustain their decreased AldoC levels, 
whereas AldoC increases again with weight regain (figure 3A). Furthermore, a large 
sustained decrease in adipocyte size was associated with success during follow-up 
(figure 3B). This is in line with the model proposed by MacLean, which argues that 
adipocyte size and functioning are returned to baseline levels only when body weight 
is fully regained (11). Although not defined as groups, these results are in line with the 
study of Mutch et al., which showed that genes regulating fatty acid metabolism were 
differently regulated by weight loss in weight maintainers and weight regainers (15). In 
addition, these results suggest that glycolysis is a major denominator of adipocyte 
size and contributes to body weight during follow-up. The amount of stored fat is a 
resultant of storage and lipolysis and raising the production of glycerolphosphate from 
glucose, which is necessary for the formation and storage of triglycerides, may there-
fore shift the balance towards growing of the adipocytes and gain of body weight. 
Change in body weight during follow-up is not only related to AldoC, but also to chan-
ges in ATGL during weight loss (figure 4). This correlation remained significant in a 
multiple regression analysis taking into account body weight loss (data not shown), 
and suggests that the amount of fat you lose from the adipose tissue during the 
weight loss phase determines what happens to the body weight afterwards. This is in 
line with the model of adipocyte cellular stress for weight regain (11, 22, 25, 26).  
A limitation of this study is that diet and physical activity were not standardized 
during the 10-month follow-up. On the other hand, due to the absence of an advise on 
diet and physical activity, this study truly reflects achievements in free-living conditi-
ons. Another limitation is the use of total adipose tissue biopsy material for Western 
blotting. Furthermore, β-actin showed no significant changes and was chosen as a 
housekeeping control to be able to compare the present results with those of other 
studies. Although the selected proteins are involved in the major steps of the glucose 
and fatty acid metabolism and may reflect the capacity of metabolic pathways, it 
should be noted that protein levels do not represent the actual flux through the path-
ways. The 10-month follow-up is a major advantage with regard to previous studies 
and indicates that the cellular response to weight loss persists during follow-up until 
body weight is regained. Another advantage is that previous findings are now confir-
med in a larger population and in combination with measurements on adipocyte size.  
In conclusion, these data show a coordinated regulation of markers for lipolysis 
and beta-oxidation during weight loss, which seems weaker during follow-up due to 
adipocyte size-related changes in HADHsc expression. AldoC as a marker for glyco-
lysis is the major denominator of adipocyte size and body weight, whereas the marker 
for lipolysis during weight loss contributes to body weight during follow-up. Upregulati-
on of ATGL and HADHsc occur in the absence of a negative energy balance and are 
triggered by adipocyte shrinkage or indicate preadipocyte differentiation. Overall, our 
findings are in line with normalization from a dysregulated obese status to an impro-
ved metabolic status. 
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Figure 2. Change in ATGL levels during weight 
loss as a function of the change in HADHsc 
levels during follow-up. 
Figure 4. Change in ATGL levels during weight 
loss as a function of the change in body weight 
(kg) during follow-up. 
  
Figure 3. Change in Aldolase C levels and change in adipocyte volume as a function of the 
change in body weight (kg) after 10-month follow-up compared to baseline. Aldolase C (A), 
adipocyte volume (µm3) (B). 
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Abstract 
An inverse relationship between sleep duration and body mass index (BMI) has been 
shown. Assessing the relationship between changes in sleep duration and changes in 
body-weight and body-composition during weight loss. 98 healthy subjects (25males), 
age 20-50y, and BMI 28-35kg/m2, followed a 2-month very low energy diet, followed 
by a 10-month period of weight maintenance. Body weight, body composition (deute-
rium dilution and air-displacement plethysmography), eating behaviour (Three Factor 
Eating Questionnaire), physical activity (Baecke) and sleep (questionnaire, Epworth 
Sleepiness Scale) were assessed prior to and immediately after weight loss and after 
3 and 10 months follow-up. Average weight loss was 10% after 2-month dieting, and 9 
and 6% after respectively 3 and 10-month follow-up. Daytime sleepiness and time to 
fall asleep decreased during weight loss. Sleep duration increased in short- and aver-
age-sleepers during weight loss. This change in sleep duration was concomitantly 
negatively correlated with the change in BMI during weight loss and after 3-month 
follow-up, and with the change in fat mass after 3-month follow-up. Short (≤7h) and 
average (>7<9h) sleepers increased their sleep duration, while sleep duration in long 
sleepers (≥9h) did not changed significantly during weight loss. Sleep duration bene-
fits from weight loss, or vice versa. Successful weight loss, loss of body-fat and 3-
month weight maintenance in short and average sleepers are underscored by an 
increase in sleep duration, or vice versa. 
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Introduction 
Parallel to the increase in the prevalence of obesity, a reduction in sleep duration is 
observed during the past decades (1, 2). Evidence is accumulating that short sleep 
duration is a risk factor for weight gain (3, 4). Consequently, it is suggested to add 
sleep duration to a growing panel of determinants that contribute to obesity (3).  
Sleep deprivation may predispose to obesity via both energy intake, energy ex-
penditure and substrate utilization (5-9). Short sleep duration can increase energy 
intake through alteration in the neuroendocrine control of appetite and reward (6, 7, 9-
12). Moreover, short sleep duration increases opportunities to eat, and in combination 
with highly available palatable foods, this can lead to an increase in energy intake 
(13). Energy expenditure can be decreased with short sleep duration by a decline in 
physical activity caused by an increased tiredness during waking hours (5) or by an 
altered thermogenesis (14). Although some studies do find an effect of short sleep 
duration on specific components of energy metabolism such as activity energy expen-
diture (7), total daily energy expenditure does not seem to be affected (7, 15). Stress 
also may play a role, through the relationship between the activity of the hypothala-
mic-pituitary-adrenal axis, insulin sensitivity and substrate utilization (16). 
The relatively short- or medium-term observational studies may elucidate mecha-
nisms supposedly inducing continuous weight gain, but whether they lead to the deve-
lopment of obesity in the long-term remains questionable. Therefore, it is necessary to 
observe whether sleep duration and body-weight including body-composition are 
related to each other and change concomitantly over the longer term.  A few studies 
have addressed this research question. Rat studies have shown a quantitative relati-
onship between sleep and the energy status of the body (17, 18), and a qualitative 
relationship between sleep and lipid/protein synthesis and degradation (17). Nedelt-
cheva et al. showed that a combined energy and sleep restriction in humans resulted 
in decreased loss of fat mass and increased loss of fat free mass (14). This suggests 
that sleep plays a role in the preservation of human fat-free mass during periods of 
energy restriction. Another long-term study showed that shifting sleep duration from a 
short to a healthier length is associated with lower adiposity gain (19). Sleep duration 
and quality at baseline were both associated with body fat loss in a moderate caloric 
restriction intervention (20). 
The studies suggest an inverse relationship between sleep duration and the deve-
lopment of body-weight. However, it is impossible to ascertain the temporal sequence 
from case-control and cross-sectional studies, since they assess sleep duration and 
body-weight concurrently. Only longitudinal study designs are suitable to investigate 
whether changes in sleep duration are followed by changes in body-weight or vice 
versa.  
The purpose of this study was to assess the relationship between changes in 
sleep duration and changes in body-weight and body-composition during weight loss 
in the long-term. More specifically it was investigated whether a temporal sequence of 
changes in sleep duration and in body-weight and body-composition could be revea-
led.  
CHAPTER 7 
80 
Material and methods 
Subjects 
150 healthy subjects aged 20-50 y with a body mass index (BMI) of 28-35 kg/m2 were 
recruited by advertisements in local newspapers and on notice boards at the universi-
ty. Subjects underwent a screening and were in good health, nonsmokers, not using 
medication (except for oral contraception) and moderate alcohol users. None of the 
subjects gained or lost more than 5 kg in the three months prior to the study. 98 sub-
jects (25 males, 73 females) completed the study. The weight loss diet consisted of 8 
weeks very low energy diet (VLED) providing 2.1 MJ/day (Modifast; Nutrition et Santé 
Benelux, Breda, The Netherlands). This diet was a protein-enriched formula diet that 
provided 50g carbohydrates, 52g protein, 7g fat and a micronutrient content, which 
meets the Dutch recommended daily allowance. Vegetables were allowed in addition 
to the diet. The weight loss period was followed by a weight maintenance period of 10 
months, in which subjects were instructed to maintain their newly achieved body-
weight without specific dietary instructions. Measurements were performed at four 
time points; before weight loss (t0), after weight loss (t2) and after 3 (t5) and 10-
months (t12) follow-up. The study was conducted according to the guidelines laid 
down in the Declaration of Helsinki and all procedures involving human subjects were 
approved by the Central Committee on Human Research and by the Medical Ethical 
Committee of the University of Maastricht. Written informed consent was obtained 
from all subjects. The study was registered in ClinicalTrials.gov (registration number: 
NCT01015508). 
Anthropometry 
Height was measured at screening to the nearest 0.1cm with the use of a wall-
mounted stadiometer (model 220; Seca, Hamburg, Germany). Body-weight was mea-
sured with subjects in underwear after an overnight fast using a calibrated scale. BMI 
was calculated by dividing body weight by height squared (kg/m2). The distribution of 
fat was investigated by measuring the waist circumference at the site of the smallest 
circumference between the rib cage and the ileac crest, with the subjects in standing 
position. Hip circumference was measured at the site of the largest circumference 
between waist and thighs. Body-composition was calculated from body volume with 
the use of air-displacement plethysmography (BodPod, Life measurement, Concord, 
CA, USA) (21) and total body water (22) as assessed with the deuterium dilution 
technique, using Siriʼs three-compartment model (23). The dilution of the deuterium 
isotope (2H2O) is a measure for total body water. Subjects wore tightly fitting bathing 
suits and a swim cap during the volume-measurements of the air-displacement 
plethysmography, and had not engaged in exercise at least 1 hour prior to the test.  
Blood parameters 
Fasted blood samples were taken and collected in EDTA containing tubes to prevent 
clotting. Plasma was obtained by centrifugation and stored at -80°C until further ana-
SLEEP DURATION DURING WEIGHT LOSS AND MAINTENANCE 
81 
lysis. Leptin concentrations were measured with the use of the human RIA kit (Millipo-
re, St Charles, MO, USA).  
Questionnaires 
Subject characteristics were assessed at all visits through specific questionnaires. To 
determine whether attitude toward food intake changed during weight loss and follow-
up, a validated Dutch translation of the three-factor eating questionnaire (TFEQ) was 
used (24). To determine the physical activity the validated Baecke-questionnaire was 
used (24, 25).  
For sleep duration the question was: ʻHow many hours do you usually sleep per 
night during week days?ʼ and ʻHow many hours do you usually sleep per night during 
weekend days?ʼ. A total weekly sleep score was calculated as ((hours sleep week 
days x 5) + (hours sleep weekend days x 2)) / 7 (5). Another question concerning 
sleep quality was: ʻHow long does it take to fall asleepʼ. Daytime sleepiness was as-
sessed through the Epworth Sleepiness Scale (ESS). Subjects rated the likelihood of 
falling asleep in eight specific situations on a 0-3 scale, with 0 meaning no chance at 
all of falling asleep and 3 meaning a high chance of falling asleep. The total score can 
range from 0 to 24, with a score of ten and higher suggesting excessive daytime 
sleepiness (26).  
Statistical analysis 
Data are presented as mean and their standard deviation (SD), unless otherwise 
indicated. ANOVA repeated measures was carried out to determine possible differen-
ces over time. Age and gender were used as covariates in all tests. Since subjects 
consisted of short sleepers (≤7 hours of sleep), average sleepers (>7 <9 hours of 
sleep) and long sleepers (≥9 hours of sleep) (3), changes in sleep duration were as-
sessed for short- and average-sleepers separately from changes in long-sleepers. 
Linear regressions were carried out to determine relationships between dependent 
and independent variables. Significance was defined as P<0.05. All of the statistical 
analyses were executed with SPSS version 16.0 for Macintosh OS X (SPSS Inc, Chi-
cago, IL). 
Results 
98 subjects (25 males, 73 females) completed the study, with an average weight loss 
of 10% after the VLED and 9% after 3-month follow-up and 6% after 10-month follow-
up compared to baseline. Body weight, BMI, fat mass, and hip circumference were 
decreased compared to baseline (table 1). Also leptin levels decreased (table 1), with 
a significant positive correlation between the change in leptin and the change in fat 
mass after 10-month follow-up (P<0.01, R2=0.32). Dietary restraint scores increased 
and disinhibition scores decreased (table 1). The change in dietary restraint scores 
was negatively correlated with the change in BMI and fat mass after 10-month follow-
up (respectively P<0.01, R2=0.17 and P<0.01, R2=0.15). The change in disinhibition 
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Table 1. Subject characteristics over time (mean±SD); at baseline (t0), after very low energy diet 
(VLED) (t2), after 3-month follow-up (t5) and after 10-month follow-up (t12) (n=98). 
 t0  t2  t5  t12  P-value 
Body weight (kg) 92.5±12.7 83.0±11.3*  84.4±12.4* 86.8±13.2 <0.001 
BMI (kg/m2) 31.9±3.2  28.7±3.1* 29.1±3.4*  29.9±3.7 <0.001 
Fat mass (kg) 38.7±7.6 31.2±7.5* 30.9±8.3 33.6±8.6 0.021 
Percentage fat mass (%) 41.8±6.6 37.5±7.3 36.5±7.7 38.5±6.8 0.196 
Waist circumference (cm) 96.9±9.6 89.4±8.7 89.7±9.3 94.2±11.3 0.089 
Hip circumference (cm) 112.7±7.5 106.1±7.5* 106.3±7.7 108.6±9.0 0.010 
Leptin concentration (µg/L) 27.5±16.0 13.5±12.2* 21.4±18.5* 21.0±16.2 0.004 
Dietary restraint 7.1±3.7 12.6±4.3* 12.1±4.4* 11.4±4.4* <0.001 
Disinhibition 6.4±2.8 4.9±2.7* 5.3±2.9* 5.7±2.7* 0.010 
Hunger 5.2±3.0 3.7±3.0 3.4±2.9 3.9±2.9 0.098 
Work activity 2.6±0.6 2.6±0.6 2.7±0.7 2.7±0.7 0.401 
Sport activity 2.3±0.7 2.4±0.6 2.5±0.7 2.4±0.7 0.255 
Leisure activity 2.9±0.6 3.0±0.6 3.0±0.6 3.0±0.6 0.624 
Sleep duration (h)      
Short and average sleepers 7.6±0.9 8.0±1.0* 7.8±1.0 7.8±0.9 0.005 
Long sleepers 9.6±0.9 8.9±1.3 8.8±1.0 8.7±1.3 0.375 
ESS 5.5±3.3 5.2±3.4 4.8±3.4 5.0±3.5* 0.036 
Time to fall asleep (min) 18.8±17.0 15.5±14.9 16.6±15.8 17.1±16.6* 0.009 
P-value; differences over time with ANOVA repeated measures  
* Significantly different from baseline (P<0.05) 
BMI, body mass index 
ESS, Epworth Sleepiness Scale  
 
scores was positively correlated with the change in BMI and fat mass after 10-month 
follow-up (respectively P<0.05, R2=0.03 and P<0.05, R2=0.03). There were no signifi-
cant differences in percentage fat mass, waist circumference, hunger scores and 
physical-activity levels over time after correcting for gender and age. ESS was decre-
ased (table 1), indicating a decrease in daytime sleepiness. Furthermore, the time to 
fall asleep slightly but significantly decreased (table 1).  
In short and average sleepers sleep duration increased during weight loss (0.4 ± 
0.7h, P<0.01). To assess whether this change in sleep duration was associated with 
changes in body-weight and body-composition, linear regression analyses were per-
formed. The change in sleep duration was negatively correlated with the change in 
BMI after weight loss and after 3-month follow-up (figure 2). After 10-month follow-up 
there was no significant correlation between the change in sleep duration and BMI. To 
assess the temporal sequence, a linear regression analysis was performed between 
the change in sleep duration during weight loss and the change in BMI after follow-up. 
These correlations were neither significant after 3, nor after 10-month follow-up. Also 
vice versa, the change in BMI during weight loss was not correlated with the change 
in sleep duration after follow-up, indicating that the changes in BMI and in sleep dura-
tion only occurred in parallel during weight loss. 
To assess whether the change in sleep duration in short and average sleepers is 
associated with the change in fat mass, linear regression analyses were also perfor-
med with the change in fat mass. During weight loss this correlation was not signifi-
cant. At 3-month follow-up the change in sleep duration was negatively correlated with 
the change in fat mass (figure 3). After 10-month follow-up there was no significant  
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Figure 1. Change in body mass index (BMI) (kg/m2) as a function of the change in sleep dur-
ation (hours) during weight loss (changes over t2-0; white circles and dotted trend line) and 
after 3-month follow-up (changes over t5-0; black circles and black trend line) in short and 
average sleepers (n=78). Linear regression BMIt2-0 vs sleep duration t2-0; P<0.05, R2= 0.09 (y = -
0.4857x -3.137) and BMIt5-0 vs sleep duration t5-0; P<0.01, R2= 0.10 (y = -0.7411x -2.9135). 
Changes over t12-0 were not significantly correlated and therefore not depicted. 
 
Figure 2. Change in fat mass (kg) as a function of the change in sleep duration (hours) after 3-
month follow-up (changes over t5-0; black circles and black trend line) in short and average 
sleepers (n=78). Linear regression Fat masst5-0 vs sleep duration t5-0; P<0.05, R2= 0.07 (y = -
1.906x -7.4817). Changes over t2-0 and t12-0 were not significantly correlated and therefore 
not depicted. 
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correlation between the change in sleep duration and the change in fat mass. As for 
BMI, also for fat mass there was no significant correlation between the change in 
sleep duration during weight loss and the change in fat mass after follow-up or vice 
versa. This again indicates that the changes in fat mass and sleep duration occurred 
in parallel until 3-month after weight loss. A multiple regression analysis of changes in 
sleep duration and changes in BMI, respectively fat mass did not increase the explai-
ned variation of changes in BMI alone. Changes in body weight and fat mass both 
after weight loss and after 10-month follow-up were however not significantly different 
between groups.  
Change in sleep duration was inversely correlated with sleep duration at baseline 
in the entire group (figure 4). At closer inspection of the data, it appeared that the 
variance in sleep duration had decreased remarkably after weight loss. Short and 
average sleepers increased their sleep duration during weight loss (respectively, n=21 
0.7±1.1h, P<0.01 and n=57 0.2±0.5h, P<0.01). Sleep duration in long sleepers did not 
significantly change during weight loss after including age and gender as covariates 
(n=20 -0.7±1.0h, P=0.37).  
 
 
 
Figure 3. Change in sleep duration (hours) as a function of baseline sleep duration (hours) in 
short and average sleepers (n=78) (changes over t2-0; white circles and dotted trend line, chan-
ges over t12-0; black circles and black trend line). Linear regression sleep durationt2-0 vs sleep 
durationt0 P<0.01, R2= 0.11 (y = -0.2876x + 2.5597) and sleep durationt12-0 vs sleep durationt0 
P<0.001, R2= 0.21 (y = -0.4204x + 3.3209). Changes over t5-0 were not significantly correlated 
and therefore not depicted. 
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Discussion 
Average weight loss was 10% after 2-month dieting (P<0.01), 9% after 3-month fol-
low-up (P<0.01) and a non-significant 6% after 10-month follow-up (P=0.05). Sleep 
duration increased in short- and average-sleepers during weight loss. This change in 
sleep duration was concomitantly negatively correlated with the change in body 
weight during weight loss and after 3-month follow-up, and with the change in fat 
mass after 3-month follow-up. Short (≤7h) and average (>7 <9h) sleepers increased 
their sleep duration during weight loss, while sleep duration in long sleepers (≥9h) did 
not change significantly. This suggests that sleep duration in short and average 
sleepers benefits from weight loss, and vice versa. 
The inverse correlations between changes in sleep duration and changes in BMI 
indicate that successful weight loss and maintenance occurs concomitantly with an 
increase in sleep duration. The slope coefficient of the correlation between the chan-
ges after 3-month follow-up was higher compared to the slope coefficient of the corre-
lation between the changes after weight loss (beta2-0= -0.5 and beta5-0= -0.7). The 
changes in BMI and in sleep duration appear to be the largest during weight loss, and 
they stabilize during the 3-month follow-up. However, after 10-month follow-up there 
was no significant correlation between the increase in sleep duration and decrease in 
BMI anymore. This might be due to the larger variation in weight maintenance, with 
some subjects regaining their lost weight, while some lost even more weight, while the 
newly achieved sleep duration was maintained overall. To assess whether an increa-
se in sleep duration would precede a decrease in BMI or vice versa, the possible 
relationship between the change in sleep duration during weight loss and the change 
in BMI during follow-up was tested in a linear regression and vice versa. No significant 
correlations were found and therefore no conclusion can be drawn on the temporal 
sequence. Longitudinal cohort studies suggested that short sleep duration is associa-
ted with future weight gain (27, 28). However, the first study cannot be generalized 
since they included persons with a high risk for psychiatric disorders (27), while the 
other study cannot exclude the possibility of reverse causation since only sleep dura-
tion was assessed at one time point (28). 
Moreover, it is impossible to disentangle cause and effect due to different study 
designs (29, 30). So far, only effects of sleep restriction have been investigated, be-
cause until now it is not known how to intervene using sleep improvement, while 
changes in body-weight mainly have been shown using diet-induced weight-loss. To 
our knowledge, so far no studies have shown spontaneous changes in body-weight 
and in sleep duration at the same time. From the presently available studies it seems 
that the parallel changes in sleep duration and BMI may have a common underlying 
cause, which can exert its effect in a parallel manner. For example, stress might act 
on sleep duration and on body-weight independently, possibly exerting a synergistic 
effect.  
The second objective of this study was to assess whether an increase in sleep 
duration from short to normal sleep duration would be associated with a larger decre-
ase in fat mass. Nedeltcheva et al. showed that a combined energy and sleep restric-
tion in humans resulted in an increased loss of fat free mass (14). This suggests that 
sleep plays a role in the preservation of human fat-free mass during periods of energy 
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restriction. However, no constructive conclusion can be drawn from studies restricting 
both energy intake and sleep duration as in the study of Nedeltcheva. Therefore, we 
assessed spontaneous changes in sleep duration during both energy restriction as 
well as a weight maintenance period. The inverse correlation between the change in 
sleep duration and the change in fat mass after 3-month follow-up suggests that in 
addition to a concomitant correlation between a change in sleep duration and weight 
loss and weight maintenance, also body-fat loss is concomitantly associated with a 
change in sleep duration or vice versa. However, adding the change in fat mass in a 
multiple regression does not strengthen the association between the change in BMI 
and the change in sleep duration. So, the association of the change in sleep duration 
with the change in fat mass might be included in the association with the change in 
BMI. Changes in body weight and fat mass during follow-up were not significantly 
different between groups, indicating that sleep duration habits did not influence body 
weight stability in the reduced obese state. 
During weight loss, sleep quality was improved with a decrease in daytime 
sleepiness and a decrease in time to fall asleep. Previous studies have shown that 
there is an interaction between sleep quality and the lipid/protein synthesis and de-
gradation (17). Minet-Ringuet et al. showed that sleep quality improved by re-feeding 
rats with alpha-lactalbumin (18). Such studies suggest that adjustments in the diet 
could be used to improve sleep in adults, while they also may improve body-weight 
regulation (31). 
Sleep duration increased in short and average sleepers during weight loss, while 
sleep duration in long sleepers did not change significantly. This suggests that sleep 
duration in short and average sleepers benefits from weight loss, and vice versa. 
Chaput et al. concluded that shifting sleep duration from a short to a healthier length is 
associated with lower adiposity gain (19). However, it is still unclear what this healthier 
sleep duration would be. For clinical implications it is important to find the optimum 
sleep duration, and by which factors it is determined, to be able to use this in combi-
nation with changes in diet and exercise, to optimize weight loss.  
A limitation of this study is the use of self-reported sleep durations, though pre-
vious studies showed good agreement between self-reported and measured sleep 
durations (32, 33). The time to fall asleep significantly decreased, however a decrease 
of only 1-2 min might not be clinically relevant. After 10 months follow up many an-
thropometric parameters, namely body weight, BMI, fat mass, waist and hip circumfe-
rence had returned to baseline values in part of the subjects, so these parameters lost 
their statistical significance with respect to the difference shown at 3 months follow up. 
This is probably due to a large variation in body-weight regain of the subjects. This 
may indicate a transient effect of the negative energy balance during the VLED, in 
part of the subjects. During weight loss subjects were allowed to eat vegetables in 
addition to the diet and results indicated that subjects during weight loss consumed a 
total of 5.2MJ/day, including the diet. In addition, effects of potential behavioural and 
metabolical changes induced by the VLED of only 5.2 MJ/day itself cannot be exclu-
ded. 
This study differentiates from previous studies by its longitudinal design to inves-
tigate the relationship between spontaneous changes in sleep duration and changes 
in body-weight and body-composition due to energy restriction. In conclusion, sleep 
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duration benefits from weight loss, or vice versa. Successful weight loss, loss of body-
fat and 3-month weight maintenance in short and average sleepers are underscored 
by an increase in sleep duration, or vice versa. 
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The subject of the thesis is body weight loss and weight maintenance as affected by 
environment and genetic predisposition. The first two studies focussed on food com-
ponents, oligofructose and Korean pine nut oil, with the potential to prevent weight 
gain by decreasing the risk of overeating through suppression of appetite. It was 
shown that 16g/d oligofructose over 13 days can be effective to reduce energy intake 
in normal-weight and overweight men and women, probably by increasing satiety 
peptides. No evidence was found for appetite suppressing effects of Korean pine nut 
oil in human subjects in the dosages tested. The next study focussed on genetic, 
physiological and behavioural factors affecting body weight, weight loss and weight 
maintenance thereafter. A high genetic predisposition score was associated with a 
high body weight and more weight loss during an 8-week energy restricted diet. Du-
ring subsequent weight maintenance, genetic effects were dominated by changes in 
eating behaviour. Adipocyte glucose and fatty acid metabolism changes in response 
to weight loss were in line with normalization from a dysregulated obese status to an 
improved metabolic status, and linked to changes in adipocyte size. Weight-loss indu-
ced increases in sleep duration underscored successful weight loss, weight mainte-
nance and body-fat loss and vice versa.  
Decreasing the risk of overeating 
Oligofructose is an inulin-type fructan thought to suppress appetite through effects on 
satiety peptides, mediated by short chain fatty acids (SCFAs) generated during colo-
nic fermentation (1). Human studies on inulin-type fructans have demonstrated acute 
effects on appetite ratings (2) and energy intake (2, 3), as well as long-term effects on 
appetite ratings (4-6), satiety peptides (7-9), energy intake (5, 8) and even body 
weight (4, 8). In contrast, some studies did not find an effect on appetite ratings (3, 7, 
8, 10) or energy intake (7, 10, 11). Assessing long-term effects of two dosages of 
oligofructose on appetite profile, satiety peptides and energy intake in normal-weight 
and overweight men and women indicated that the highest dosage oligofructose 
(16g/d) can be effective to reduce energy intake, probably by increasing the satiety 
peptides. 
Korean pine nut oil is another potential appetite suppressing food component, alt-
hough results from previous studies were contradictive. Human studies demonstrated 
acute effects on satiety peptides (12), while no effects on appetite ratings (12) or 
energy intake were found (13). Assessing acute effects of two dosages of Korean pine 
nut oil triacylglycerol (TAG) on appetite ratings and energy intake in normal to over-
weight women indicated that 6g of Korean pine nut oil TAG is not sufficient to sup-
press appetite and energy intake.  
The inconsistent results in the literature for both oligofructose and Korean pine 
nut oil studies are probably caused by differences in study designs. Dosage, timing of 
dosing regime, methods and study population influence results and need to be taken 
into account in designing a study. Type and texture determine the mechanism of acti-
on of the food component and thus timing of the dosing regime. Piloting can help 
ascertain the sensitive moment in time and is essential for optimizing timings within a 
study design.  
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Although evidence for an effect of oligofructose on energy intake in a sufficiently 
powered and well-designed study is provided, this does not necessarily imply a de-
creased risk of overeating in real-world food environments. In addition to the physiolo-
gical factors discussed above, also psychological and social factors are involved in 
meal termination and initiation. There is a large inter-individual variation in the risk of 
overeating due to the variability in the sensitivity to gut-peptide signals (14, 15), to 
modulators as circadian rhythm and sleep (16, 17) and feelings of appetite and dietary 
restraint (18, 19). Previous studies suggest that reward deficiency can lead to over-
consumption (20, 21). Hence, the palatability of the food component and its control 
within a study should be equal. It is hypothesized that eating whatever an individual 
likes in the presence of hunger, prevents reward deficiency in the absence of hunger 
thereafter (22, 23). Since the palatability of most energy-controlled diets, like high-
protein diets, is not high, a food component influencing energy intake and possibly 
body weight should additionally be as highly rewarding as possible. Other factors 
involved in food intake regulation can influence the effect of an appetite suppressing 
food component in a real-world environment. 
A food component proven to have an effect on appetite and energy intake, does 
not necessarily affect body weight. It is questionable whether an appetite suppressing 
food component can affect body weight in the absence of energy restriction. There is 
a need to carefully draw conclusions about effectiveness from these studies and tran-
slate this to health claims. Most importantly, appetite suppressing food components 
might help consumers stick to a diet, especially in periods of weight maintenance after 
weight loss, when suppressing appetite may help overcome the weight-loss induced 
elevated appetite. Concerning the food components tested in this thesis, oligofructose 
can be effective as an appetite suppressing food component decreasing the risk of 
overeating, although effectiveness in real-world environments and an independent 
effect on body weight regulation remains questionable. 
Genetic predisposition 
A high genetic predisposition score (GPS) from six single nucleotide polymorphisms 
(SNPs), already associated with obesity-related traits, was associated with a high 
body weight. Focusing on weight loss, twin studies have demonstrated a larger varia-
bility between pairs than within pairs on the response to long-term negative energy 
balance (24, 25). Short-term weight loss success was associated with a high GPS 
from the six SNPs studied. It is thought that genes associated with obesity-related 
traits must have an effect on either energy intake or energy expenditure. However, 
genetic factors might influence body weight regulation indirectly as proposed in the 
dual intervention point model (26-28). Genetically determined upper and lower boun-
daries define the points at which active physiological regulation becomes dominant, 
and between which mainly behavioural factors determine body weight regulation. A 
high GPS would result in individuals becoming heavier due to the wider boundaries 
and thus less strict body weight regulation. In addition, a high GPS would result in 
individuals losing more weight irrespective of baseline body weight, since more weight 
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can be lost before boundaries are reached and physiology takes over. SNPs associa-
ted with body weight can also have an effect on weight loss success. 
Genetic differences can explain 40-70% of the inter-individual variation in obesity 
susceptibility (29), although only a small fraction is explained by the obesity-
associated loci identified so far (30-32). The indirect influence of genetic factors as 
suggested in the dual intervention point model might explain why only a small fraction 
of the variation can be explained by the loci found so far. Elucidating genetic variants 
is further complicated by gene-gene and gene-environment interactions that can mask 
the effect of a genetic variant (33). Thus, it is important to study identified loci in longi-
tudinal studies, to elucidate the pathways underlying the association between genetic 
factors and body weight and weight loss, in order to understand the genetic contributi-
on. 
Effects of both six SNPs as well as changes in eating behaviour on long-term 
weight loss maintenance were assessed in the long-term weight loss study. Previous 
studies have shown that an increased dietary restraint is associated with success in 
weight maintenance (34-36). Results from the weight loss study showed that long-
term weight loss maintenance is associated with a large increase in dietary restraint 
and a large decrease in disinhibition. These changes in eating behaviour were inde-
pendent of and dominated genetic effects during long-term weight loss maintenance.  
To conclude, during a negative energy balance weight loss success is determined 
by genetic factors that are also associated with body weight. However, during weight 
maintenance thereafter success is mainly determined by changes in eating behaviour.  
Adipose tissue metabolism 
Weight loss results in nutrient deprivation at which adipocytes need to respond rapid-
ly, and has indeed shown to result in changes in metabolic processes within adipocy-
tes (37-40). The results from the weight loss study showed that changes in adipocyte 
size and glucose and fatty acid metabolism in response to weight loss are in line with 
normalization from a dysregulated obese status to an improved metabolic status. In 
contrast, other studies found preferential trafficking of dietary fat to adipose tissue at 
whole-body level in a weight-reduced state (41, 42), supported by the formation of 
new adipocytes (41), thereby favoring weight regain. Changes in adipocyte lipolysis 
and fatty acid trafficking in response to weight loss were associated with weight loss 
maintenance. Changes in adipocyte size as well as metabolism were sustained during 
weight maintenance until weight was regained, as previous literature suggested (43). 
The cellular stress model suggests that weight-loss induced adipocyte shrinking re-
sults in cellular stress that activates processes to increase adipocyte volume back to 
original levels, thereby resulting in weight regain. This suggests that a less intensive 
energy restriction might be more effective in the long-term, since it induces less cell 
shrinking, therefore less cellular stress, thus less weight regain. 
Glycolysis was shown to be the major denominator of adipocyte size, and chan-
ges in adipocyte metabolism were correlated with changes in adipocyte size as pre-
viously proposed in the cellular stress model (44-46). This link between adipocyte size 
and metabolism highlights the importance of measuring adipocytes size in addition to 
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adipocyte metabolism. Results show that shrinkage due to the type of embedding of 
the adipose tissue can be ignored when comparing before and after weight loss. Fur-
thermore, plastic embedding of adipose tissue provides more accurate and sensitive 
results. 
Sleep 
Literature has shown inverse associations between sleep duration and body weight in 
adults (47, 48). During puberty changes in body weight were associated with changes 
in sleep duration (49). Focusing on weight loss, it has been shown that sleep duration 
influences success of an energy-restricted weight loss intervention (50, 51). Sponta-
neous changes in sleep duration throughout the weight loss study indicated that sleep 
duration normalizes during energy-restricted induced weight loss. Shifting sleep dura-
tion from a short to a healthier length is associated with lower adiposity gain during a 
long-term follow-up (52). However, it is still unclear what this healthier sleep duration 
would be and how to improve sleep duration and quality other than by weight loss. 
Animal studies have shown an interaction between sleep quality and diet (53, 54), 
suggesting that adjustments in the diet could be used to improve sleep in adults (55). 
Successful weight loss, weight maintenance and body-fat loss was underscored 
by an increase in sleep duration and vice versa, in line with previous studies (50, 51). 
Longitudinal cohort studies suggest that short sleep duration is associated with future 
weight gain (56, 57). Sleep duration was assessed throughout the study, but no signi-
ficant results revealing a temporal sequence were found. Interpretation of results 
should be done carefully, since cause and effect cannot be disentangled (58, 59). 
Sleep duration might have an indirect effect on body weight, or the parallel changes 
observed have a common underlying cause.  
Conclusions 
- Consumption of 16g/d oligofructose over 13 days reduces energy intake in nor-
mal-weight and overweight men and women, probably by increasing the satiety 
peptides.  
- Addition of 6g Korean pine nut oil to a meal is not sufficient to suppress appetite 
and energy intake. 
- Weight-loss success is determined by genetic factors that are also associated 
with body weight. 
- Changes in eating behaviour dominate genetic effects during long-term weight 
loss. 
- Embedding related shrinkage of adipose tissue can be ignored when comparing 
adipocytes before and after weight loss.  
- Plastic embedding of adipose tissue provides more accurate and sensitive re-
sults for fat cell size. 
- Glycolysis is associated with adipocyte size and body weight. 
- Changes in adipocyte lipolysis during weight loss are associated with changes in 
body weight during follow-up.  
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- Changes in adipocyte glucose and fatty acid metabolism in response to weight 
loss are in line with normalization from a dysregulated obese status to an impro-
ved metabolic status.  
- Sleep duration normalizes during weight loss. 
- Weight-loss induced increases in sleep duration underscore successful weight 
loss, weight maintenance and body-fat loss and vice versa.  
Future perspectives 
Appetite suppressing food components might help consumers adhere to changes in 
eating behaviour necessary for successful weight loss maintenance. There are sever-
al points that need to be addressed when designing a study investigating potential 
appetite suppressing food components. The type, form and dosage of the food com-
ponent can be tested in a pilot study to determine the proper timing of dosing regime 
and methods used. Furthermore, factors influencing the inter-individual variability in 
risk of overeating might be taken into account when defining the study population. 
Future research could focus on understanding the supposed mechanism of the food 
component, as well as the influence of other processes involved in food intake regula-
tion.  
There is a need to control statements and health claims concerning the effects of 
food components investigated in studies. Consumers should be made aware of the 
broader context of weight control, instead of a too simplistic promise that an appetite 
suppressing food component can improve their weight control. Food components 
shown to suppress appetite and reduce energy intake in the short-term can be further 
investigated on the long-term and for effects on body weight regulation. The European 
Food Safety Authority (EFSA) suggests that effects on appetite should be accompa-
nied by corresponding reductions in energy intake. The effects should be sustainable, 
proving the absence of compensation and be continuous during repeated dosing over 
a minimum of 28 days (60). For claims regarding weight loss, significant changes in 
body weight need to be of appropriate duration, a minimum 3 months, and under 
specified conditions (60). These specific conditions are important to differentiate 
whether a product helps sustaining a diet, rather than having a positive effect in a diet, 
contributing to a proper definition of a claim. Studies taking into account EFSA criteria 
will result in scientifically based food claims and more transparency in research as 
well as industries and governments, thereby improving awareness of consumers. 
Concerning the understanding of the genetic contribution to body weight as well 
as weight loss and maintenance, it is important to investigate gene-gene and gene-
environment interactions. Loci already associated with obesity by genome-wide asso-
ciation studies (31, 32), should be investigated in longitudinal cohort studies to eluci-
date the pathways that underlie the obesity-susceptibility.  
With regard to adipocyte metabolism, future research should further investigate 
cellular stress involved in the response of adipocytes to weight loss (61). Whether a 
less intensive energy restriction is more effective with regard to weight loss success, 
possibly via lowering cellular stress, could be important for clinical implication. The link 
found between cell size and functioning emphasizes the need to include adipocyte 
size measurements in studies investigating adipocyte metabolism. Techniques used 
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to measure cell size, need to be carefully selected taken into account the possibilities 
as well as sensitivity and accuracy. Cell size distribution and turnover are already part 
of the literature (62, 63), but deserve further investigations.  
Research concerning sleep might focus on understanding the mechanisms corre-
lating sleep and body weight. Investigating ways to improve sleep other than weight 
loss is important as well as to disentangle cause and effect, whether such an impro-
vement of sleep also induces spontaneous body-weight loss and successive weight 
maintenance. Furthermore, finding the optimum sleep duration, if existing, could be of 
particular importance for clinical implications. 
To put the current knowledge in a broader context of clinical implications for obe-
sity treatments, successfulness of weight loss achieved by dieting and weight mainte-
nance thereafter depends on both quantitative as well as qualitative changes in ener-
gy intake. Qualitative changes might be reached by the addition of appetite suppres-
sing food components as discussed above, but also changes in macronutrient com-
position. High protein diets have shown to contribute to successfulness of weight loss 
and maintenance thereafter by increasing satiety as well as by a fat-free mass sparing 
effect, stimulating a sustained basal energy expenditure (64). In addition, psychologi-
cal guidance and behavioural therapy might improve weight loss maintenance, alt-
hough it has a risk of being time-consuming and costly. Optimizing factors as discus-
sed in this thesis might contribute to success. Beside energy restriction, there are also 
other strategies to lose weight with each different success rates. So far no drug has 
been found that produces significant and sustained weight loss without side effects. 
Bariatric surgery is often more effective, but very radical. Another strategy is increa-
sing levels of exercise, but the level of activity required to be effective is beyond the 
ability of most individuals to sustain. Next to optimizing weight-loss success rates, it is 
essential to put more focus on prevention of obesity. 
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Obesity results from a positive energy balance over time and can be reversed by 
weight loss. Weight loss is most commonly achieved by energy restriction resulting in 
a negative energy balance. However, successful long-term weight loss is counter-
acted by homeostatic adaptations in response to weight loss, creating an elevated 
appetite and suppressed energy expenditure promoting weight regain. Moreover, 
there are large inter-individual differences in the susceptibility to become obese as 
well as the success rates for weight loss and maintenance. This thesis addresses 
food components that might help decreasing the risk of overeating by suppressing 
appetite and addresses genetic, physiological and behavioural factors involved in 
weight loss and weight maintenance thereafter. 
The effects of two potential appetite suppressing food components, oligofructose 
and Korean pine nut oil, were investigated in study designs considering dosage and 
time of dose regime. Consumption of 16g/d oligofructose, the highest dosage tested, 
reduced energy intake in normal-weight and overweight men and women, probably by 
increasing the satiety peptides. Dosages of 3 and 6g Korean pine nut oil were not 
sufficient to suppress appetite and energy intake. Thus, oligofructose is a potential 
appetite suppressing food component to decrease the risk of overeating. The effec-
tiveness of appetite suppressing food components in reducing energy intake and body 
weight in real-world food environments, without being in the context of an energy-
restricted diet is questionable. However, appetite suppressing food components might 
help consumers stick to a diet, especially in periods of weight maintenance after 
weight loss, when suppressing appetite may help overcome the weight-loss induced 
elevated appetite. 
In the weight loss study it was examined whether body-weight and short and long-
term weight loss were affected by six candidate single nucleotide polymorphisms 
(SNPs) and by changes in eating behaviour, or by an interaction between these ge-
netic and behavioural factors. A high genetic predisposition score from the six SNPs 
was associated with a high body weight and more short-term weight loss. Further 
research is needed to elucidate the pathways underlying the genetic contribution to 
obesity-susceptibility. Long-term weight loss was associated with a large increase in 
dietary restraint and a decrease in disinhibition. During long-term weight loss, genetic 
effects were dominated by changes in eating behaviour. The latter emphasizes the 
importance behavioural changes for weight maintenance.  
During weight loss and maintenance, changes in ALDOC as a marker of the gly-
colysis were associated with adipocyte size and body weight, whereas changes in 
body weight during follow-up were associated with changes in ATGL as a marker of 
lipolysis during weight loss. Changes in adipocyte glucose and fatty acid metabolism 
in response to weight loss were in line with normalization from a dysregulated obese 
status to an improved metabolic status. Changes in adipocyte size as well as metabo-
lism in response to weight loss were sustained during weight maintenance until weight 
was regained. Studies investigating adipose tissue metabolism should include meth-
ods to determine adipocyte size as a major determinant of endocrine functioning of 
adipocytes. Shrinkage due to the type of embedding of the adipose tissue can be 
ignored when comparing before and after weight loss. Plastic embedding of adipose 
tissue provides more accurate results than paraffin embedding.  
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Literature indicated associations between sleep duration and body weight, initiat-
ing sleep as a study parameter in weight loss maintenance interventions. Changes in 
sleep duration showed that sleep duration normalizes during weight loss. Successful 
weight loss, weight maintenance and body-fat loss was underscored by an increase in 
sleep duration and vice versa, without elucidating the temporal sequence. Future 
research might disentangle cause and effect and investigate ways to improve sleep, 
and whether such an improvement of sleep also induces spontaneous body-weight 
loss and successive weight maintenance. 
In conclusion, appetite suppressing food components like oligofructose can de-
crease the risk of overeating and might help individuals to stick to an energy-restricted 
diet. Optimizing factors like eating behaviour, changes in adipocyte metabolism and 
sleep as discussed in this thesis might contribute to success of body weight loss and 
maintenance.  
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Overgewicht is het gevolg van een positieve energiebalans gedurende een langere 
periode en is omkeerbaar door gewichtsverlies. Gewichtsverlies wordt meestal bereikt 
door het verlagen van de energie-inname, resulterend in een negatieve energieba-
lans. Handhaving van gewichtsverlies wordt echter bemoeilijkt door homeostatische 
aanpassingen als gevolg van gewichtsverlies zoals verhoging van de eetlust en verla-
ging van het energiegebruik. Verschillen tussen individuen duiden er op dat ook aan-
leg hierbij een rol speelt. Dit proefschrift richt zich op voedingscomponenten die de 
eetlust kunnen beperken en op erfelijke, fysiologische en gedragsmatige factoren die 
betrokken zijn bij gewichtsverlies en gewichtsbehoud na gewichtsverlies. 
De eetlust-onderdrukkende voedingscomponenten die werden onderzocht waren 
oligofructose en olie uit de pitten van de Koreaanse pijnboom. Het tijdstip van toedie-
ning en dosering werden gebaseerd op een voorstudie. Een dosis van 8g oligofructo-
se bij het ontbijt en bij de lunch verlaagde de energie-inname bij het diner, waarschijn-
lijk door het verhogen van verzadigingshormonen. Een dosis van 3 en 6g olie uit de 
Koreaanse pijnboompitten was niet toereikend om eetlust en energie-inname te on-
derdrukken. Oligofructose is dus een eetlust-onderdrukkende voedingscomponent die 
het risico op overmatige energie-inname mogelijk kan verminderen. De effectiviteit 
van eetlust-onderdrukkende voedingscomponenten in het verlagen van de energie-
inname en lichaamsgewicht in het dagelijks leven vereist nog nader onderzoek. Eet-
lust-onderdrukkende voedingscomponenten kunnen consumenten mogelijk onder-
steunen bij het volhouden van een dieet tijdens gewichtsbehoud na gewichtsverlies 
door onderdrukking van de door het gewichtsverlies geïnduceerde toename in eetlust. 
In de studie naar gewichtsverlies is onderzocht of gewicht en gewichtsverlies over 
een korte en lange periode beïnvloed werden door variatie in de basenvolgorde van 
het erfelijk materiaal (single nucleotide polymorphisms; SNPs), door veranderingen in 
eetgedrag, of door een interactie tussen deze erfelijke en gedragsmatige factoren. Op 
basis van 6 erfelijke variaties kon een score worden berekend voor de erfelijke belas-
ting en het bleek dat er een verband bestond tussen een hoge score en een hoog 
lichaamsgewicht en meer gewichtsverlies over een korte periode. Verder onderzoek is 
nodig om uit te zoeken hoe het verband tussen de erfelijke belasting en de kans op 
het ontwikkelen van overgewicht kan worden verklaard. Gewichtsverlies over een 
langere periode bleek in verband te staan met een grote toename in geremd eetge-
drag en een afname in ontremd eetgedrag. Tijdens gewichtsverlies over langere ter-
mijn werd de invloed van de erfelijke variatie  overschaduwd door de veranderingen in 
eetgedrag. Dit laatste benadrukt het belang van gedragsmatige veranderingen voor 
gewichtsbehoud na gewichtsverlies. 
Tijdens de fasen van gewichtsverlies en gewichtsbehoud werd de concentratie 
van diverse eiwitten in het vetweefsel gemeten. Er bleek een duidelijk verband te 
bestaan tussen veranderingen in ALDOC als marker voor de glycolyse en vetcelgroot-
te en lichaamsgewicht. Veranderingen in lichaamsgewicht tijdens de fase van ge-
wichtsbehoud vertoonden een verband met veranderingen in ATGL als marker voor 
de lipolyse gedurende gewichtsverlies. Veranderingen in het glucose- en vetzuurme-
tabolisme van de vetcel in reactie op gewichtsverlies waren in overeenstemming met 
de overgang van een ontregelde naar een verbeterde metabole status. Veranderingen 
in zowel vetcel-grootte als -metabolisme in reactie op gewichtsverlies bleven tijdens 
gewichtsbehoud gehandhaafd totdat het lichaamsgewicht weer toe ging nemen. Deze 
SAMENVATTING 
105 
resultaten geven aan dat in studies naar de rol van het vetmetabolisme bij gewichts-
regulatie, metingen van de vetcelgrootte als een bepalende factor voor het endocriene 
functioneren van vetweefsel, meegenomen dienen te worden. Onze ervaring heeft 
geleerd, dat bij het vergelijken van vetcelgrootte voor en na gewichtsverlies krimp als 
gevolg van de manier van inbedden van het vetweefsel verwaarloosd kan worden. 
Het inbedden van vetweefsel met behulp van plastic levert nauwkeurigere resultaten 
op dan inbedden met behulp van paraffine.  
Recente literatuur duidt op een verband tussen lichaamsgewicht en slaapduur. 
Het hier beschreven onderzoek liet zien dat gewichtsverlies en verlies van lichaams-
vet gepaard gaan met een toename in slaapduur en omgekeerd zonder oorzaak en 
gevolg te kunnen verklaren. Hiervoor is nader onderzoek nodig. Verbetering van slaap 
zou hiermee een bijdrage leveren aan het succes van gewichtsverlies en gewichtsbe-
houd. 
Concluderend, oligofructose kan als eetlust-onderdrukkende voedingscomponent 
het risico op overmatige energie-inname verlagen en een ondersteunende rol spelen 
bij het handhaven van een energieverlaagd dieet. Het optimaliseren van factoren als 
eetgedrag, veranderingen in vetcelmetabolisme en slaap, zoals besproken in dit 
proefschrift, kunnen bijdragen aan succesvol gewichtsverlies en gewichtsbehoud. 
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